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Traditionally, metastatic colorectal cancer has been treated using cytotoxic chemotherapy 
but the development of immunotherapeutic agents has afforded higher durable remission 
rates and more tolerable side effect profiles in a small subset of patients.  Immunotherapy 
treatments are currently approved for the treatment of microsatellite instability high 
subgroup that comprises four percent of metastatic colorectal cancer. However, 
immunotherapy treatments have little clinical activity in the microsatellite stable 
subgroup, which encompasses the majority of colorectal cancers.  In this phase II trial, 
we propose to study the efficacy and safety of a three-drug regimen comprised of two 
immunotherapy treatments, programmed death 1 and cytotoxic T-lymphocyte associated 
protein 4 blockade, and a cyclooxygenase inhibitor in the microsatellite stable subgroup. 
This combination aims to increase the treatment eligible proportion of colorectal cancers 
















CHAPTER 1: INTRODUCTION 
 
1.1 BACKGROUND  
Immuno-oncology is a new paradigm in cancer treatment that has the potential to 
provide unprecedented and robust tumor regression as well as increased survival 
compared to traditional chemotherapeutic agents in several cancers even at an advanced 
stage. The first immune checkpoint inhibitor (ICI), a human cytotoxic T-lymphocyte 
antigen 4 (CTLA-4)-blocking antibody named ipilimumab (Yervoy; Bristol Myers 
Squibb) was approved in 2011 and many others began development based on its 
unmatched success.1 ICIs are now a standard of care for various cancer types such as 
metastatic melanoma, non-small cell lung cancer (NSCLC) and renal cell carcinoma.2 
In colorectal cancer (CRC), immunotherapies have achieved remarkable efficacy 
shown by significantly prolonged progression free survival (PFS) and safety profiles that 
are favorable compared to traditional chemotherapy, but only in a small subset. Three ICI 
therapies were approved recently for a small subset of metastatic colorectal cancers 
(mCRC): pembrolizumab (Keytruda), nivolumab (Opdivo) and the combination 
treatment nivolumab and ipilimumab (Yervoy).3-5 This subset is comprised of patients 
with the biomarker called microsatellite instability high (MSI-H) or deficient mismatch 
repair (dMMR) that makes up 15-20% of the CRC and about 4% of the mCRC 
population.6 
1.2 STATEMENT OF THE PROBLEM  
While immune checkpoint inhibitors are capable of causing tumor regression and 
improved overall survival with fewer side effects compared to traditional chemotherapy, 





the response rate of ICIs in CRC and specifically in microsatellite stable/proficient 
mismatch repair (MSS/pMMR) colorectal cancer is paramount. 
1.3 GOALS AND OBJECTIVES 
Prior preclinical data suggest that the combination of checkpoint inhibition and COX 
inhibition might achieve a higher response rate in a subset of MSS CRC patients.  
The aim of this study is to find whether the combination treatment of anti-PD-1/anti-
CTLA4 and anti-COX treatment will enhance the response rate in MSS mCRC, while 
maintaining an adequate safety profile. We will also evaluate the efficacy measures of 
PFS and OS, toxicity profiles and associations with known biomarkers. 
1.4 HYPOTHESIS 
This parallel assignment, randomized allocation phase II trial is designed to study the 
hypothesis that the combination of PD-1 and CTL4 blockade and COX-2 inhibition or 
COX-1 and 2 inhibition significantly increases the objective response rates (ORR) 
(23.7%) compared to the historical response rate of 8.7% with PD-1/CTL4 blockade 
alone in MSS/pMMR mCRC that has progressed on previous treatment with cytotoxic 
chemotherapy with irinotecan, fluorouracil and oxaliplatin. The expected effect size of 
15% will be tested for statistical significance.  
1.5 DEFINITIONS 
PD-1: Programmed death 1 receptor, co-inhibitory receptor found on effector T cells 
PD-L1: Programmed death ligand 1 found on tumor cells  
CTLA-4: Cytotoxic T-lymphocyte associated protein 4, co-inhibitory receptor found 
on recently activated T cells  
CD80/CD86: Ligand for CTLA-4, found on tumor-associated antigen presenting cells 
(APCs) 
Pembrolizumab (Keytruda): Humanized anti-PD-1 antibody (Merck & Co.) 
Nivolumab (Opdivo): Fully human anti-PD-1 antibody (Bristol-Myers Squibb) 
Ipilimumab (Yervoy): Fully human anti-CTLA-4 monoclonal antibody (Bristol-
Myers Squibb) 
Celecoxib (Celebrex): A selective COX-2 inhibitor (Pfizer)  





FOLFOX: Combination chemotherapy containing oxaliplatin with fluorouracil (5FU) 
and folinic acid 
FOLFIRI: Combination chemotherapy containing fluorouracil (5FU), folinic acid and 
irinotecan  
FOLFOXIRI: Combination chemotherapy containing oxaliplatin with fluorouracil 
(5FU), folinic acid and irinotecan  
Capecitabine (Xeloda): Antimetabolite chemotherapy agent (generic) 
5FU(Adrucil): fluorouracil, an antimetabolite chemotherapy agent (generic) 
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CHAPTER 2: REVIEW OF THE LITERATURE 
2.1 INTRODUCTION  
We searched relevant clinical trials; articles and conference abstracts published in the 
English language in PubMed and Ovid MEDLINE, Cochran Review and 
ClinicalTrials.gov between the years 1980 and 2018. The searches were conducted with 
the MeSH subject headings of “immunotherapy”, “colorectal cancer”, “metastatic”, 
COX-2 inhibitors” and “microsatellite stable”. Other non-MeSH terms we searched were 
“deficient mismatch repair”, “proficient mismatch repair”, “checkpoint inhibitor”, COX 
inhibition” and “combination therapies”.  
2.1a Incidence of Colorectal Cancer 
Colorectal cancer (CRC) is the third most common cancer as well as third leading 
cause of cancer mortality in the US7 and the second leading cause of cancer mortality 
worldwide.8 Although the recent advances in screening improved both incidence and 
mortality rates, The National Cancer Institute estimates that there will be 140,250 new 
cases and 50,630 deaths associated with CRC in the United States in 2018. CRC 
comprises 8.1% of new cancer diagnoses and the median age at diagnosis is 67. mCRC or 
Stage IV CRC that is defined by spread of the disease to distant sites in the body, 
comprises 21% of the CRC population. The incidence is slightly higher in men than 
women, and in African Americans, compared to other races.9 
2.1b Prognosis 
Based on data from Surveillance, Epidemiology and End Results (SEER) from 2008 
to 2014, the overall 5-year survival rate for CRC is 64.5% in the US. The 5-year survival 
rate for localized CRC is 89.8%, for regional is 71.1%, and for distant metastases is 





right- vs. left-sided tumor, microsatellite instability (MSI-H)/deficient mismatch repair 
(dMMR) vs. microsatellite stable (MSS)/proficient mismatch repair (pMMR), KRAS, 
BRAF and NRAF mutation status.10  
2.1c Current Treatment Guidelines  
As metastatic tumors are rarely resectable or treatable solely by radiation and 
generally require systemic treatment. The main systemic treatment options for mCRC are 
traditional cytotoxic chemotherapy, anti-VEGF or EGFR therapy. 10  
First line chemotherapeutic agents such as FOLFOX, FOLFIRI, Capecitabine and 
5FU/leucovorin have been used with or without the anti-angiogenic agent bevacizumab. 
For high tumor burden or rapidly progressing disease the quadruple chemotherapy 
FOLFOXIRI can be considered. These agents can be used as neo-adjuvant therapy or 
post-resection and are generally administered every 2-3 weeks for several cycles. The 
efficacy and response rate of chemotherapy varies based on the regimen. In a 
representative study looking at chemotherapy versus chemotherapy with an anti-
angiogenic agent, overall survival (OS) in mCRC was 15.6 months with IFL (irinotecan, 
5FU and leucovorin) and 20.3 months with IFL plus bevacizumab, corresponding to a 
hazard ratio of 0.66 for death (p<0.001). The response rates were 44.8% and 34.8% 
respectively.11  
For refractory mCRC the drugs regorafenib or trifluridine/tipiracil are recommended 
and offer a modest survival benefit.10 A meta-analysis evaluating data for 702 patients in 
12 studies, assessing the efficacy of regorafenib found summary progression free survival 
rates of 3.34 months and overall survival rates of 7.27 months but the response rate was a 
modest 2%.12 The side effects of chemotherapy vary based on the combination but the 





and cold sensitivity. Some side effects, such as neuropathy can be treatment limiting and 
irreversible.10  
Recent advances in immunotherapy afforded new checkpoint blockade options for a 
small subset of mCRC patients, discussed in Section 2.2. 
2.2 REVIEW OF EMPIRIC STUDIES 
 
2.2a Immune Checkpoint Inhibitors in the Treatment of Colorectal Cancer 
The immune system recognizes foreign invaders such as bacteria and viruses but it 
can also mount an attack against our own deviant cells, such as cancer cells. Attributed to 
the number of mutations they accumulate, cancer cells can display abnormal epitopes 
called neo-antigens on their surface. Neo-antigens recognized by the immune system can 
trigger an immune attack leading to the destruction of the cancer cells. Checkpoints built 
into the system to help curb aberrant autoimmune reactions toward healthy cells. The co-
receptor portion of his double system, consisting of the antigen presented by an antigen 
presenting cell (APC) and a co-receptor whose activation can prevent immune system 
activation is a frequent target of cancer immune evasion. Some neoplasms acquire 
mechanisms to evade destruction by T-cells by hijacking these checkpoints leading to the 
dampening or curbing of the immune attack despite neo-antigen recognition. This 
immune evasion generally takes place by negative regulation of T-cell activation either 
during primary activation or during the memory forming immune response phase.1  
The two most well studied of these checkpoints are cytotoxic T-lymphocyte-
associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1) and its ligand 
programmed death-ligand 1(PD-L1). CTLA-4 is a co-inhibitory receptor found on 
recently activated T cells whose ligand is found on tumor associated APCs. PD-1 





programmed death ligand 1 is found on tumor cells. Many other newly discovered 
checkpoints are now being investigated as future therapeutic targets. 
Immune checkpoint inhibition (ICI) is a strategy that aims to stimulate immune cells, 
mainly T cells. Several ICI agents have emerged, commonly targeted pathways being 
PD-1 using the humanized antibody pembrolizumab, or the fully human antibody 
nivolumab. Anti-CTLA-4 antibodies such as the fully human antibody ipilimumab are 
also available.  
Releasing these breaks to aid tumor destruction via checkpoint inhibition has 
achieved unprecedented success in treating certain tumor types. A meta-analysis of 13 
studies with 3,513 immunotherapy treated small cell lung cancer patients and 3,072 
chemotherapy/placebo treated patients found greatly improved progression free survival 
(PFS)(odds ratio 1.81, [95% CI 1.36, 2.42; P<0.0001]) and overall survival (OS) 
(P<0.0001).13 
While ICIs can cause sustained responses in selected patients, based on cancer type 
and specific host tumor markers, there are several obstacles to be overcome. One of the 
most pressing concerns is the low response to immune checkpoint inhibitor mono-
therapies. The response rates have been inconsistent both amongst different types of 
cancers, and histologically different cancers within a specific cancer type. The overall 
response rate to immune checkpoint therapy ranges from 15% with ipilimumab14 to up to 
40% with PD-1/PD-L1 blockade, including those patients whom only achieved a partial 
response to treatment.15 The response rates can be as high as 61% in melanoma with PD-
1/CTLA-4 (nivolumab/ipilimumab) treatment16 however, melanoma has been showing 





exception of melanoma, ICI response rates are between one quarter to one half of 
recipients.  
It is vital to improve both the response rate to immune checkpoint inhibitor treatments 
in mCRC as well as to increase the efficacy of the treatment signified by extended 
progression free survival (PFS) and overall survival (OS). The discovery of biomarkers 
that can identify patients who are likely to respond to checkpoint inhibitor treatment is 
crucial to achieving this goal.  
Mismatch repair (MMR) or microsatellite instability (MSI) are biomarkers that have a 
large impact on ICI treatment response rates and prognosis. Mismatch repair is a 
mechanism cells use to repair DNA damage during cellular replication. Mismatch repair 
deficient (dMMR) or Microsatellite Instability High (MSI-H) is a small subset of CRC 
that has a high mutation rate. A higher mutation burden translates into a larger number of 
neo-antigens displayed in cancer cells’ MHC I molecules. Antigen presentation renders 
these tumors easier to be recognized by the adaptive immune system, higher density of 
TIL (tumor infiltrating lymphocytes) leading to a more efficient elimination by ICIs.17 
This increased immunogenicity in MSI-H tumors is termed as being “hot”, versus MSS 
tumors that are labeled “cold” tumors based on their diminished immunogenicity 
attributed to the lack or paucity of TILs.18  
Historically, the MSI-H/dMMR and MSS/pMMR subsets of CRC respond very 
differently to single agent immunotherapy. While in MSI-H/dMMR CRC the objective 
response rate was 40%, to the anti-PD-1 antibody pembrolizumab (Keytruda Merck & 





Generally, the dMMR/MSI-H subset comprises only 15-20% of all colorectal cancers, 
and as the stage of the disease increases, the portion of the dMMR/MSI-H CRC 
decreases. Only 4% of Stage IV CRC is dMMR/MSI-H.6 Thus, only a very small portion 
of mCRC lends itself to ICI treatment, with the majority of mCRC that is MSS/pMMR 
failing to demonstrate meaningful clinical activity.   
As the MSI-H/dMMR tumor biomarker is predictive of response to PD-1 checkpoint 
inhibitor therapy6, guidelines published by the American Society of Clinical Pathology, 
College of American Pathologists, Association of Molecular Pathology and the American 
Society of Clinical Pathology recommends universal MSI and mismatch repair (MMR) 
testing in all mCRC patients since 2017.19 See Appendix B for MMR testing and MSI 
classification. As only 4% of the mCRC population possesses this biomarker, the 
majority of mCRC patients are excluded from ICI treatment options. It is paramount to 
further elucidate the differences, especially regarding molecular patterns, cytokine 
expression and tumor infiltrating lymphocyte (TIL) content between MMS and MSI-H 
tumors.17  
Although mutation burden and in turn the number of neo-epitopes cancer cells display 
in a specific tumor seem to be the most important factor in predicting response to ICIs, a 
new paradigm in immune-oncology recognizes that other factors are at play, especially 
given that the MSI-H/MSS classification does not always correlate with response to ICI 
therapy.  In fact, genomic profiling of tumors from over 6000 patients found that about 
3% of MSS CRC have high mutation burden (HMB MSS).20 Of note, some MSS/pMMR 





chemokine expression similarly to their MSI-H/dMMR counterpart and importantly, have 
similar prognosis.17 
The best ICI response rates were seen in MSI-H/dMMR CRC, but even with the 
combination of ipilimumab and nivolumab, only a little more than half of this population 
responds. Although microsatellite instability is not a perfect marker for ICI response, it is 
the strongest one we have. The challenge is to coax the MSS tumors to behave more like 
their MSI-H counterparts.17 Current advances in using Immunoscore as a new biomarker 
might yield a better indicator for checkpoint therapy success. If we accept Immunoscore 
as a valid predictor of response rate, the challenge will become to increase a certain 
tumor’s Immunoscore.  
 Immunoscore is a scoring system based on the density of CD3+ and CD8+ T-Cell 
effectors within the tumor and its invasive margin.21 It was validated for Stage I-III CRC 
by a large international consortium.21 Another study found that Immunoscore is also 
predictive of DFS (disease free survival) and OS (overall survival) in mCRC.22 Refer to 
Appendix C for the description of the Immunoscore scoring system. 
The two ICI monotherapies approved for chemotherapy pre-treated MSI-H/dMMR 
mCRC are pembrolizumab and nivolumab.3-5 The first agent to be approved was the anti-
PD-1 antibody pembrolizumab, based on studies conducted on eleven cancer types, 
including CRC. In this study 52% of CRC patients responded to pembrolizumab and the 
estimated 1-year PFS was 64%. As per protocol, the patients stopped therapy at 2 years 
and none had recurrence at the median follow up of 8 months.5 The extended durable 






Nivolumab, another PD-1 blocker was approved for MSI-H/dMMR CRC patients 
who progressed on traditional chemotherapy after the Nivolumab monotherapy arm of 
the CheckMate 142 trial found a 31.1% response rate in MSI-H/dMMR CRC with a 
corresponding 1-year survival of 50%.3  
2.2b Clinical Efficacy of Ipilimumab and Nivolumab  
The complexity and redundant nature of cellular signaling often favors combinatorial 
treatments. Ongoing efforts aim to test combinations of ICI and radiation, targeted 
therapy, chemotherapy and anti-angiogenic agents.2 These combinations can either block 
a single checkpoint pathway more effectively such as concurrent PD-1/PD-L1 blockade 
or simultaneously target distinct pathways. Attempts to combine different ICIs such as 
anti-CTLA-4 ipilimumab and the anti-PD-1 nivolumab (Opdivo; Bristol-Myers Squibb) 
have been increasingly effective in several cancer types including colorectal cancer2. 
Just recently, based on the results of the CheckMate 142 study, ICI therapy using the 
anti-PD-1/anti-CTLA4 nivolumab and low dose ipilimumab was approved for MSI-
H/dMMR CRC that has progressed following treatment with a fluoropyrimidine, 
oxaliplatin, and irinotecan.23 The response rate using this combination improved to 55% 
over 31.1% with nivolumab only and the 1-year survival increased to 71% from 50%. 
The price of higher response rate and efficacy was higher frequency of CTCAE Grade 3 
and 4 adverse events that increased from 20% with nivolumab only, to 32% with the 
combination. These adverse events, however, were overall manageable.4  
While the Phase II study CheckMate 142 focused on the combination of CTLA-4 
blockade and PD-1 blockade in the MSI-H mCRC patient population, responses were 
also seen amongst the much smaller arm consisting of MSS patients.  23 MSS patients 





1.9 months). The median PFS was minimal compared to the MSI-H/dMMR cohort’s that 
was not reached after 33 PFS events. It is notable that the responses were not associated 
with tumor PD-L1 expression levels in either cohort. Furthermore, responses were not 
associated with BRAF/KRAS mutation or history of Lynch syndrome in the MSI-
H/dMMR cohort.4  
While these results are promising, addition of an immunomodulating drug could 
increase ORR and improve survival in both subgroups.  
2.2c Immune Mediated Adverse Events using Nivolumab and low-dose Ipilimumab 
Treatment related adverse events (TRAEs) associated with nivolumab and low dose 
ipilimumab treatment, are mainly immune mediated adverse events (IMAE). IMAEs can 
affect any of the main organ systems and have a diverse range of manifestation. During 
the CheckMate 142 trial the most common TRAEs found were diarrhea (22%), fatigue 
(18%) and pruritus (17%) followed by pyrexia and elevated AST (15%).4 The in depth 
safety analysis was published separately.24 TRAEs resolved in the majority of the patients 
(71-96%), except for endocrine adverse events which only resolved in 40% of patients. 
The discontinuation rate due to an adverse event (AE) remained low at 13% and there 
were no treatment related deaths reported.  
 The addition of COX-inhibitors in the current study might modulate these adverse 
events, which will be closely monitored and recorded throughout the study with the goal 
of early recognition, as early recognition and treatment of IMAEs with or without the 
need for steroids, could improve outcomes in ICI treatment.25 See Appendix D for 





2.2d Management of Immune-related Adverse Events  
Immune related adverse events (irAE) will be managed by the recommendations set 
forward by the American Society of Clinical Oncology (ASCO) Clinical Practice 
Guideline, briefly outlined in Appendix R. For further information and organ specific 
management, refer to the published guidelines.25 
2.2e The Role of the COX Pathway in Colorectal Cancer  
In this section we will discuss the role of COX pathway in colorectal cancer and 
specifically in MSS CRC and few of the mechanisms that are thought to be at play. 
COX-2 is overexpressed in many human cancers such as colorectal, pancreatic, lung, 
breast and stomach cancers.27 Additionally, research in different cancer types show that 
microsatellite instability has an inverse relationship with COX-2 expression levels. In 
gastric cancer, microsatellite instability is inversely proportional to COX-2 expression. 28 
Karnes et al. found that a subset of colorectal carcinomas with microsatellite stable 
phenotype (MSS) shows increased expression of COX-2 compared to colon cancer with 
the MSI-H phenotype.29 Furthermore, response to COX-2 inhibitors is reduced in cell 
lines with reduced COX-2 expression in in vitro experiments.30 The COX-2 
overexpression in MSS CRC therefore could be predictive of COX-2 inhibitor treatment 
success.  
The COX-2 enzyme can be inhibited both by steroids (by inhibiting the release of the 
COX substrate arachidonic acid) and non-steroidal anti-inflammatory drugs (NSAIDs) 
that either inhibit COX-1 and COX-2 enzymes or selectively inhibit COX-2.31 COX-1/2 
(Aspirin, Bayer) or selective COX-2 inhibitors such as celecoxib (Celebrex, Pfizer) are 





The product of the COX-2 pathway is prostaglandin E2 (PGE2), a vital homeostatic 
factor that has a wide range of functions in many body systems, including several roles in 
modulating immune responses.31 The COX-2 pathway plays a dual role in cancer. 
Paradoxically, while PGE2 is considered to be a mediator of inflammation via activation 
of dendritic cells, it has also been shown to suppress innate and antigen-specific immune 
responses by suppressing the dendritic cells’ ability to interact with naïve, effector and 
memory T-cells, and suppressing other effector functions associated with cytotoxic T-
cells (CTL) and natural killer cells (NK). Thus while PGE2 stimulates acute local 
inflammation, it suppresses immune function by effector cells such as CTL, T-helper 
1(Th1) and NK cells, especially in the later stages of inflammation.31 This is thought to 
prevent the tissue-damaging actions of nonspecific inflammation during chronic 
inflammatory conditions such as chronic infections or cancer.32.33 PGE2 is also implicated 
in promoting angiogenesis.33 Together PGE2’s angiogenic effect, T-cell suppressive and 
pro-inflammatory activities contribute to immune evasion and are advantageous for 
tumor formation.31  
Another proposed function that may contribute to the COX pathway’s T-cell 
suppressive action is it’s direct involvement with checkpoint molecules such as PD-L1 an 
important target of ICI therapy. Botti at. Al found that COX-2 expression positively 
correlates with PD-L1 expression in both primary tumors and metastases in melanoma in 
vitro.34 Furthermore, inhibition of COX-2 by celecoxib down-regulated the expression of 
PD-L1 in two different human melanoma cell lines.34  
Another proposed mechanism for the COX pathway’s involvement in immune 





pathway. IDO1 has an essential role in regulating tryptophan catabolism by degrading 
tryptophan and therefore represses tryptophan-dependent T-cell populations,35 a 
mechanism that is at least in part responsible for the tumor immune escape. Hennequart 
and colleagues showed that COX-2 expression drives constitutive expression of IDO1 
which in turn represses the T-cells in human tumor cells in seven human cell lines, 
including colorectal cancer. COX-2 inhibition by celecoxib treatment promoted rejection 
of IDO1 expressing human tumor xenografts. Of note, the reduction of IDO1 was 
associated with infiltration by CD3+ and CD8+ T cells.35 
The most compelling argument for using anti-inflammatory drugs such as COX 
inhibitors (alone or in combination with ICIs) is the elimination of chronic inflammation 
that leads to immunosuppression, by inhibiting myeloid-derived suppressor cells 
(MDSCs). MDSCs are myeloid precursors that are unique to cancer, and less frequently 
to autoimmune diseases,38 thus they are an excellent target for anti-cancer drug 
development. Their exclusive role is to provide a protective environment to cancer cells 
and they were found to be the most important mediator of chronic inflammation, which in 
turn, leads to immunosuppression.39  
The tumor microenvironment (TME) that includes the stroma and infiltrating cells is 
gaining attention as an important site of immune modulation. The TME has several cell 
types that help protect cancer cells by secreting cytokines and chemokines thereby 
altering myelopoiesis. Out of these tumor harboring cell types MDSCs seems be the most 
crucial, by promoting the formation of Tregs and other cell types that help protect cancer 





Targeting MDSCs, is a complex problem. The candidate drug needs to be an anti-
inflammatory drug without the immune-suppressive effects.41 COX inhibitors, such as 
celecoxib or aspirin fit this description in that they decrease inflammation and are not 
immunosuppressive but do not target cytokines of chronic inflammation as a 
monotherapy.42 However in combination with ICI they were shown to decrease both 
MDSCs, Tregs and immunosuppressive cytokines. The preclinical murine study that 
explored the effect of celecoxib plus PD-1 blockade in melanoma and breast cancer cells 
found reduced MDSC and Treg population in the TME, as well as reduced cytokines IL-
1β and IL-6. The other preclinical murine study also reported reduced cancer promoting 
growth actors and chemokines, including IL-1, IL-6 and IL-8.43 Importantly, MDSCs, the 
chronic inflammation marker C-reactive protein and the immune suppressive cytokines 
can be measured.38  
In summary, COX inhibitors decrease inflammation and are not immunosuppressive 
but do not target the cytokines of chronic inflammation as a monotherapy,42 thus are not 
thought to be effective in preventing tumor progression. In the murine study conducted 
by Zelenay et. al. COX inhibition had no effect on the progression of implanted COX-
competent melanoma cells.27 COX inhibitors have been used as primary or secondary 
prophylaxis or as an adjunct to other modalities in colorectal adenomas with moderate 
efficacy, discussed in the next section.  
2.2f Clinical Efficacy of COX Inhibition  
Celecoxib and aspirin have both been used in colon adenocarcinomas as chemo-
preventive agents. A large study that followed up four randomized trials and pooled 
individual patient data of over 14,000 patients showed that the long-term use (mean 





incidence and mortality due to CRC. The 20-year risk of colon cancer was reduced in the 
cohort taking aspirin (incidence hazard ratio [HR] 0.76, 0.60-0.96, p=0.02), and also 
reduced mortality (HR 0.65, [95% CI, 0.48-0.88, p=0.005]).44 Although the studies being 
analyzed differed in many characteristics including median duration of treatment, 
methods of post trial follow up or proportion of current smokers, they were all double 
blinded placebo controlled trials. This analysis demonstrates the degree to which aspirin 
monotherapy was able to affect patients even after years of treatment.   
A much larger meta-analysis of 281,063 CRC patients in 37 RCTs found that aspirin 
reduced CRC incidence and mortality in a dose dependent manner (risk ratio [RR], 0.74 
[95% CI, 0.57-0.97]) for high-dose (≥325 mg daily dose) and (RR, 0.81 [95% CI, 0.67-
0.98]) for very-low-dose (≤100 daily dose)).45 Although the previous two meta-analyses 
used different statistical methods, they both showed association of chemopreventive 
aspirin use and reduced mortality and the second meta-analysis showed a dose dependent 
relationship.   
Similarly, celecoxib monotherapy was shown to be efficacious in secondary 
prevention. A systematic review that examined three RCTs and three post-trial studies of 
6,559 patients found that celecoxib doses between 400-800mg/day, when used for the 
duration of 1-3 years showed statistically significant reduction of the recurrence of 
advanced colorectal adenomas (RR 0.42 [95% CI, 0.34-0.53]) compared to placebo. 
Subgroup analysis using 400mg/day celecoxib demonstrated very similar effects on 
advanced adenomas (RR 0.45, [95% CI, 0.35-0.58]) compared to placebo, regardless of 





Celecoxib is also used as an adjunct in addition to anticancer agents in the treatment 
of several cancer types. A large meta-analysis that analyzed data from 11 trials found that 
when used in combination with cytotoxic chemotherapeutic agents in advanced 
colorectal, non-small cell lung cancer (NSCLC), prostate, breast and ovarian cancer, 
celecoxib significantly increased the objective response rate (ORR) (RR 1.20, [95% CI, 
1.06-1.36, P=0.005]) but had no effect on 1-year mortality (RR 1.02; [95% CI, 0.92-1.13; 
P = 0.68]).47 
These studies provide evidence for aspirin or celecoxib use for primary and secondary 
prevention or as an adjunct in CRC. The new 2016 USPSTF guideline now suggests the 
use of <100mg daily dose of aspirin for primary CRC prevention for patients without 
bleeding risk.48 In summary, COX inhibition offers some protection against colorectal 
cancer but is not intended as a monotherapy for treatment. 
2.2g Drug-Related Adverse Events Associated with COX Inhibitors 
The most common side effects of aspirin are GI disorders such as heartburn, nausea, 
vomiting and abdominal pain. Elevated liver enzymes were also reported as well as very 
rare cases of renal impairment and acute renal failure. Bleeding time is also prolonged, 
leading to increased risk of bleeding.78  
The most serious adverse events associated with the use of aspirin are gastrointestinal 
bleeding, hemorrhagic stroke53 and less frequently aspirin-exacerbated respiratory 
disease. A meta-analysis found the incidence of GI bleeds in 65,987 patients taking 50-
1500 mg daily dose of aspirin for the mean duration of 28 months to be 2.47% compared 
to 1.42% in patients taking placebo.49 Thus, the incidence of GI bleed associated with 
aspirin use remains low. Furthermore, bleeding risk with low to high doses of aspirin 





chemoprevention in CRC. A large systematic review and meta-analysis examining 
281,063 patients in 37 RCTs taking aspirin for chemoprevention found the dose range of 
75-325 mg/day safe regarding cardiovascular mortality and major GI bleeding among 
patients of average risk.45  
The most common side effects of celecoxib are also GI symptoms, such as dyspepsia, 
abdominal pain, nausea and diarrhea.79 Celecoxib has a more favorable safety profile 
compared to other non-selective NSAIDs regarding the risk of gastrointestinal injury. 
Celecoxib was found to have significantly lower incidence of endoscopically observed 
duodenal ulcers compared to 500mg twice-daily Naproxen. Doses from 50mg up to 
400mg twice daily were studied and scientists found no correlation between celecoxib 
dose and the incidence of duodenal ulcers.50 Concerns remain regarding the increased 
cardiovascular risk of thromboembolism associated with selective COX-2 inhibitors. A 
large randomized controlled trial (PRECISION) that recruited 24,081 arthritis patients 
found that 100mg twice daily celecoxib was non-inferior to other NSAIDs such as 
ibuprofen or naproxen regarding cardiovascular risk.51 The cardiovascular risks were 
found to be similarly low in the CRC population. A meta-analysis that included 
randomized controlled trials and post-trial studies of 6579 CRC patients investigated the 
efficacy and safety of various celecoxib doses (200mg twice daily, 400mg daily or 
400mg twice daily) versus placebo for secondary chemoprevention in CRC found the 
400mg once daily dosing to be optimal without increasing cardiovascular risks. 
Cardiovascular risk compared to placebo with the 400mg once daily dose was 1.01 [95% 





cardiac events (3.42 [95% CI, 1.56-7.46]).46 Of note, the currently approved doses of 
celecoxib are 200-400mg daily for osteoarthritis and rheumatoid arthritis.52  
2.2h Management of Drug-Related Adverse Events associated with COX Inhibitors 
Patients who are considered high risk for aspirin associated GI bleed, such as patients 
with previous GI bleed or ulcer or concomitant use of clopidogrel will be excluded from 
the study. Patients enrolled in the study will be closely monitored for signs and symptoms 
of GI bleed.  
The most effective strategies for reducing the risk of aspirin related upper GI bleed is 
switching to an alternative antiplatelet therapy or concomitant use of proton pump 
inhibitor.54 Proton pump inhibitors will be offered to patients as a prophylactic measure. 
As switching to an alternative therapy is not an option in this case, aspirin use might have 
to be discontinued in cases of serious GI bleeding.  
A possible adverse effect associated with both aspirin and selective COX-2 inhibitors 
is aspirin-exacerbated respiratory disease (AERD) that presents with moderate to severe 
asthma symptoms and rhinosinusitis. Patients with asthma or asthma known to be 
exacerbated by aspirin use are excluded from the study. Management of AERD includes 
discontinuing aspirin or COX-2 inhibitor use and pharmacological management of 
asthma symptoms and chronic rhinosinusitis.55 
Interruption of treatment with aspirin or celecoxib will be permitted in case of the 
need for elective surgery or biopsy. Aspirin and celecoxib will be discontinued 7 days 






2.2i Preclinical and Clinical Data Regarding Combination Checkpoint Inhibition 
and COX Inhibition  
Several pre-clinical works using in vivo animal models and in vitro human cell 
cultures and some clinical data of ad hoc data or tissue marker analysis of large 
prospective cohort studies shows promise for the combination of PD-1 blockade and 
COX-2 inhibition in CRC and multiple other cancer cell lines.27,43,56 Accumulating 
evidence indicates that the combination of checkpoint inhibition and COX-2 inhibition 
could be a viable treatment option for several cancer types as an adjunct to ICI. The 
combination of COX inhibitors and PD-1 blockers resulted in decreased tumor growth 
compared to PD-1 monotherapy alone in murine melanoma models.27 The inhibition of 
the COX-2 pathway combined with anti-PD-1 therapy improved the eradication of 
tumors and increased the number of tumor-specific cytotoxic T lymphocytes (CTLs) in 
human cell cultures from advanced ovarian cancer patients.56  
The seminal work by Zelenay at. al. presented compelling pre-clinical evidence for 
the use of COX inhibition as an adjunct to ICIs. His team found that COX inhibition 
works synergistically with checkpoint inhibition via anti-PD-1 blockade inducing 
eradication of tumors in in vivo experiments using the CT26 syngeneic murine colorectal 
tumor model. Of note, the CT26 murine colorectal cells were found to share molecular 
features with MSS colorectal tumors.57 In their immunomic, genomic and transcriptomic 
characterization study, Castle and colleagues found that CT26 cells lack mutations in the 
Mlh1 and Msh2 mismatch repair genes that are associated with microsatellite instability. 
CT26 cells were also found to lack a Braf gene mutation that is also frequently associated 
with the MSI-H phenotype. Overall CT26 cells were found to have a molecular makeup 





Zelenay and colleagues showed that COX induces PGE2 in tumors that disrupts 
myeloid function and propose that PGE2 dependent suppression of myeloid cell 
activation could be an additional mechanism of tumor immune escape in addition to the 
immunoediting process whereby the immune system selects for less immunogenic tumor 
cells. Furthermore, they showed that COX ablation in tumors re-establishes immune 
control. A possible mechanism investigated by the researchers was the reduction of tumor 
promoting factors such as Interleukin 6 (Il6) and Il1β expression by COX ablation 
leading to increased levels of antitumor pathway mediators.  
Importantly, similar effects were achieved by pharmacological reduction of PGE2 
levels. They propose that COX inhibition synergizes with checkpoint blockade therapy 
via anti-PD-1 blockade, and its efficacy is higher than either PD-1 blockade or COX 
inhibition alone. This synergistic effect of COX inhibition and ICIs could revolutionize 
ICI therapy in colorectal cancer. Since the COX inflammatory signature and signaling 
pathway is conserved in humans27, and its inhibitors are readily available, it is a viable 
target of investigation in clinical studies. 
Another pre-clinical study explored the effect of local and systemic delivery of 
celecoxib and PD-1 blockade on melanoma and breast cancer in tumor-bearing mice. 
Researchers found that the treatment elicited potent and sustained antitumor effect by 
enhancing T cell immunity, reduced immunosuppression and reducing inflammation and 
tumorigenesis.43 The drug combination acted synergistically, to enhance the presence of 
CD4+ interferon (IFN)ϒ+ and CD8+ IFNϒ+ T cells both within the tumor and in the 
immune system. Importantly, the combination treatment reduced myeloid derived 





is a marker for chronic inflammation. Once again, Il-6 and Il-1β were shown to be 
suppressed, leading to diminished angiogenic and pro-inflammatory tumor 
microenvironment. Thus, combination PD-1 blockade and COX-2 inhibition 
simultaneously targeted both the immunosuppressive network and the chronic 
inflammation in the tumor environment, both of which are thought to dampen ICI 
therapeutic efficacy.39 Of note, PD-1 blockade caused an increase of PGE2, which was 
subsequently completely abolished by celecoxib treatment. 
Aspirin (a dual COX-1 and COX-2 inhibitor and antiplatelet agent) may be more 
effective in synergizing with ICIs than selective COX-2 inhibition by celecoxib. Zelenay 
and colleagues found that aspirin was more effective than celecoxib in tumor eradication 
when combined with PD-1 inhibition in mouse experiments.27 The increased efficacy of 
dual COX inhibition is thought to be due to the inhibition TGF-β (released by platelets) 
associated with COX-1 inhibition and anti-platelet activity. TGF-β is thought to attenuate 
tumor response to PD-L1 blockade by contributing to the exclusion of CD8+ T-cells.58 
TGF-β is even thought to be one of the main drivers of immune evasion in colon cancer 
metastasis.59 In mouse experiments, COX inhibition alone using aspirin had no effect on 
the progression of implanted melanoma cells, compared to the effect with combination 
with anti-PD-1 therapy where COX inhibition promoted a much more rapid tumor 
regression than anti-PD-1 alone, and notably was more efficacious than selective COX-2 
inhibition.27  
While both studies were carried out in mouse models, the COX pathway and the 
COX-dependent inflammatory signature is remarkably conserved in humans. In addition 





melanoma and found very similar mRNA expression levels of tumor promoting 
cytokines.27 
While the previous studies were carried out mainly in murine models, the same 
principles have been demonstrated using human tissue cultures. Combined PD-1 
blockade and disruption of COX-2 signaling lead to the eradication of tumors and 
increased the number of tumor-specific cytotoxic T lymphocytes (CTLs). Furthermore, 
the study showed that tumor-derived prostaglandin E2 (PGE2) plays an important role in 
depressing CTL function.56 
Clinical evidence for the synergistic effect of aspirin (a COX-1 and COX-2 
inhibitor) and immune checkpoint blockade comes from the analysis of data collected in 
two large prospective cohort studies.60 Hamada and colleagues examined data collected 
using questionnaires and analyzed tumor samples from the participants of the Nurses’ 
Health Study that followed 121,701 women and Health Professional’s Follow Up study 
that included 51,529 men. 621 records were chosen for analysis based on the availability 
of tumor samples, data of PD-L1 expression level measured by immunohistochemistry 
and aspirin use. Patients were observed from 1976 and 1986 respectively, to death or 
January 1st 2012, whichever came first. Regular aspirin use was defined as either 
standard-dose or low-dose, or both taken two or more times per week. Post-
diagnosis aspirin use with colorectal cancer–specific survival differed by PD-L1 (CD274) 
expression status (Pinteraction < .001) and overall survival (P=0.004) compared with aspirin 
nonusers. In patients with low PD-L1 expression, the multivariable-adjusted hazard ratios 
(HR) for regular aspirin users were 0.16 (95% CI, 0.06 to 0.41). Patients with high level 





1.01 95% CI 0.61 to 1.67). Of note, this differential prognostic association of aspirin use 
and PD-L1 expression status seemed consistent among MSS and MSI-H colorectal 
tumors. A weakness of this study was that chemotherapy regimens were not available for 
most participants. Although data collected on the patients who did have available 
chemotherapy descriptions, post-diagnosis aspirin used was not associated with 
chemotherapy use, the use of different regimens could introduce a confounder.  
We were interested in the dose-response relationship of which we could model our 
aspirin experimental arm. Unfortunately, secondary analysis was lacking statistical power 
to establish a dose-response relationship, although there seemed to be a prognostic 
association by PD-L1 expression status.  
In summary, while this study followed patients who underwent cytotoxic 
chemotherapy or received no treatment and did not include patients whom underwent ICI 
therapy, it reveals an important association between the efficacy of post-diagnosis aspirin 
use and PD-L1 expression level in patients with CRC. This data points to a stratum of 
CRC that will benefit from post-diagnostic aspirin use and may have very important 
implications in corroborating added aspirin use in combination with ICI.   
Several phase I/II trials investigating ICI + COX inhibition that are either preparing 
to or are currently actively enrolling patients with various solid tumors, three of which 
are carried out with colorectal cancer patients specifically or include them in their eligible 
cancer type. The choice of ICI is either nivolumab or nivolumab and ipilimumab at 
standard doses and aspirin at the doses 200-325mg daily or celecoxib at the doses of 200-





discuss the similarities and differences in proposed rationale. See Appendix P for a 
summary of these trial designs.  
 The current phase II study titled Nivolumab, Ipilimumab and COX2-inhibition in 
Early Stage Colon Cancer: an Unbiased Approach for Signals of Sensitivity (NICHE) 
[NCT03026140] is set out to investigate the combination of nivolumab, ipilimumab and 
celecoxib as a neoadjuvant therapy in early stage CRC in both the MSS and MSI-H 
subgroups. This neoadjuvant approach administers the drug combination for the short 
period of 6 weeks in anticipation of shrinking the tumor prior to surgery. The regimen for 
the active comparator group (Group 1) consists of a single dose of ipilimumab 1mg/kg on 
day 1 and two cycles of nivolumab 3mg/kg on day 1 and 15, respectively. The 
experimental group (Group 2) is given a single dose of ipilimumab 1mg/kg on day 1, two 
cycles of nivolumab 3mg/kg on day 1 and 15 and 200mg celecoxib daily until the day 
before surgery. While all MSI-H patients are allocated to Group 1, MSS patients are 
randomized to Group 1 or Group 2. Compared to this trial design, our proposed study 
will recruit CRC patients with metastatic disease that this trial excludes. Notably, we will 
use a double the dose (400mg) of celecoxib proposed here. Although the study design of 
neoadjuvant treatment might warrant a lower dose. Furthermore, our study avoids 
randomizing MSS participants into an ipilimumab/nivolumab treatment group only that 
has previously shown an inadequate response by using a cross trial comparison arm. 
While our approach might have decreased validity due to slight institutional differences 
in how variables are operationalized, it will expose participants to the least possible harm.  
Another current Phase II study, titled PD-1 Antibody Combined With COX Inhibitor 





combination of nivolumab and COX inhibition in MSI-H/dMMR CRC. As mentioned 
earlier, about 3% of MSS lesions are high TMB (tumor mutation burden), thus they 
would be included in this study. This trial differs from ours in that it restricts its 
participants to high TMB that is generally associated with a faulty DNA repair 
mechanism and adds celecoxib to modulate the inflammatory tumor environment. This 
would theoretically increase the proportion of CRC that responds to ICI treatment but 
continues to exclude the majority of CRC patients.  
The current Phase II study titled An Open Label Phase II Study Combining 
Nivolumab and Celecoxib in Patients With Advanced " Cold " Solid Tumors (NICE-
COMBO) [NCT03864575] investigates the combination of nivolumab and celecoxib in 
late stage solid tumors. Although this study did not specify CRC as an eligible cancer 
type, the characteristics of the cancers treated, e.g. “cold”, “advanced solid tumors” “with 
an indication of treatment with anti-PD1 antibodies” technically include MSI-H mCRC, 
for which the nivolumab/ipilimumab combination is FDA approved. This trial is similar 
to ours in that it aims to treat “cold” tumors. 
The phase Ia/Ib trial investigates safety in a dose escalation of radiation 0.5-3Gy in 
addition to a fixed ICI and proposed immunomodulatory regimen (aspirin, 
cyclophosphamide) dose. The ipilimumab/nivolumab regimen is combined with a 300mg 
daily aspirin dose and cyclophosphamide. This is the only Phase I study examining ICI 
plus immunomodulation, due to the radiation dose escalation component, while the drug 
doses remain fixed.  
The Phase II study titled PRIMMO aims to treat refractory cervical and endometrial 





(Vitamin D, aspirin, cyclophosphamide and lansoprazole). The aspirin dose used was 
325mg daily. This study also examines the combination of ICIs and immunomodulation 
including aspirin in a stage IV solid tumor type.  
In conclusion, there is mounting evidence to support translational continuation of 
pre-clinical work with ICI and COX inhibition combination.  
2.3 REVIEW OF POSSIBLE CONFOUNDING VARIABLES 
There are well-studied prognostic markers that pertain to the general CRC population. 
The prognostic markers within the MSS mCRC population are less well studied, 
especially regarding to ICIs treatment. In this section, we will discuss prognostic markers 
as they pertain to confounding study data.  
The general prognostic markers of CRC are lymph node involvement, presence of 
metastases, right- versus left-sided tumor, microsatellite instability (MSI-H)/deficient 
mismatch repair (dMMR) vs. microsatellite stable (MSS)/proficient mismatch repair 
(pMMR), KRAS, BRAF and NRAF mutation status.10 As we will be restricting our study 
population to MSS metastatic CRC, the known prognostic markers that remain as 
possible confounders are right- versus left-sided tumor, KRAS, BRAF and NRAF 
mutation status. KRAS confers poor prognosis in the MSS CRC according to the 
guideline from the American Society for Clinical Pathology, College of American 
Pathologists, Association for Molecular Pathology, and American Society of Clinical 
Oncology, thus it will be considered a confounder. 
Myelosuppression is a known adverse event associated with chemotherapeutic 
agents10 that is theoretically a negative predictor of ICI therapy response, although not 
well studied in CRC. Thus, previous and especially recent cytotoxic chemotherapy might 





Right- versus left-sided tumor was found to be a strong prognostic marker of survival. 
A large meta-analysis and systematic review of 1,347 846 patients found that left sided 
primary tumor location was associated with a markedly reduced risk of death (HR, 0.82; 
95% CI, 0.79-0.84; P < 0.001) independently of stage, race, use of chemotherapy, year of 
study (1995-2016), number of participants and quality of study.61 While this study did not 
perform a sub-group analysis based on MSI status and didn’t explore ICI use, its results 
must be considered. As a strong prognostic predictor in the general CRC population, the 
location of the primary tumor should be considered a confounder and be factored into the 
final data analysis.  
Age and sex were both found to be prognostic factors specifically for ICI use.62 
Increased age is associated with immunoscenescence that leads to decreased lymphocyte 
function and exhaustion of T-cell function.63 Male patients seem to respond better and 
demonstrate significantly increased survival when treated with ICI therapy, but the role 
of sex in this phenomenon is largely unknown.62  
Another strong prognostic predictor specifically in the mCRC population we will be 
restricting is the presence of brain or leptomeningeal metastases. While a rare type of 
metastases with an incidence in CRC are 0.6-3.2%, 64 it is a strong prognostic predictor of 
morbidity and mortality. The median survival after brain metastases diagnosis is 2.6- 7.4 
months64, compared to any distant metastases that are associated with a median survival 
of approximately 20 months.65 Due to its paucity, restriction of brain metastases will not 
likely to have a significant effect on external validity, while increasing internal validity.  
In summary, we will take several precautions in treating variables that can have an 





metastases, that were rare enough to pose threat to the external validity. Possible 
confounders discussed here and proposed mediators discussed in Section 2.4i will all be 
considered in the post-trial exploratory analysis. 
2.4 REVIEW OF METHODOLOGY 
This section will provide evidence to support methodology proposed in this study. Please 
refer to Chapter 3 for detailed description of methodology and study protocols. 
2.4a Study Design  
The proposed study will be a single-center, open label, Phase II exploratory study 
with randomized parallel assignment of two arms investigating the effects of 
nivolumab/ipilimumab + celecoxib or aspirin compared to nivolumab/ipilimumab alone 
in patients with MSS/pMMR mCRC. We will report efficacy, safety, biomarker 
association and patient reported outcomes (PRO) in both MSS/pMMR cohorts. All 
participants will receive the same weight-based dose nivolumab/ipilimumab + fixed 
dose celecoxib or aspirin regimen. The MSS/pMMR cohort will not receive the 
nivolumab/ipilimumab only regimen due to the low objective response rate (2/23) and 
short PFS (1.4 months) observed in this cohort in the CheckMate 142 trial.4 The mean 
PFS associated with the current standard of care therapy of regorafenib is 3.34 months 
and the associated response rate is 2%.12 The MSS/pMMR cohort will be compared to 
historical control of the CheckMate 142 MSS/pMMR cohort with an identical ICI 
regimen in combination with COX inhibition and comparable follow up time. This 
cross-trial comparison will allow for sparing the MSS/pMMR cohort from being 
randomized into a treatment group that has shown less than optimal results previously.  
Although each treatment component separately has well known and tolerable 





2.4b Patient Selection and Study Population 
This study will compare two single treatment arms to the historical control of the 
CheckMate 142 study MSS cohort and will use the same patient selection criteria to 
increase the validity of this cross-trial comparison.4 This study will recruit adults of age ≥ 
18 years with histologically confirmed distant metastatic spread of CRC (Stage IV as 
defined by TNM staging criteria), confirmed MSS/pMMR genotype who has progressed 
on previous treatment with cytotoxic chemotherapy using fluoropyrimidine, oxaliplatin 
and irinotecan. In the CheckMate 142 study, the restriction of previously treated patients 
was necessary to conform to the FDA approved indication for the low dose ipilimumab 
and nivolumab combination, although patients who declined the use of chemotherapeutic 
agents were included. In this study, we are using this regimen for a population (MSS 
mCRC) for whom it is not FDA approved, but will keep the restriction of previous 
treatment to increase the validity of the cross-trial comparison. The population of interest 
will have ECOG performance status of 0 or 1, evaluated within one month before 
randomization.  
The exclusion criteria include high dose prednisone (> 10mg daily dose) required for 
autoimmune disease. As prednisone reverses the effect of ICIs, it would dampen 
treatment effect. Patients with prior treatment with the anti-PD1, anti-PD L1/L2 and anti 
CTL-4 immune checkpoint or other agent targeting T-cell co-stimulation or immune 
checkpoint pathways are excluded from this study. Patients with serious uncontrolled 
medical disorders are also excluded, as these confounding disorders would affect 
morbidity and mortality. Some organ function parameters are also dictated by the added 





acute or severe hepatic or renal failure or bleeding diatheses.66 Patients must demonstrate 
adequate organ function as defined in Appendix O. 
Patients must have a lesion that is accessible for a biopsy or has had a biopsy with 
accessible tissue in the past 6 months and the patient is willing to provide this tissue for 
study purposes. 
Patients with brain metastases will be excluded from this study. Brain metastases are 
rare in the CRC population. A systematic review found that the incidence of brain 
metastases in CRC are 0.6-3.2%.64 They, however, carry increased mortality and 
morbidity. The median survival after brain metastases diagnosis is 2.6- 7.4 months64 
compared to about 20 months with any metastases65 and thus brain metastases diagnosis 
must be excluded from our study as a potential confounder.  
Patients must not be taking Non-steroidal Anti-inflammatory Drugs (NSAIDs), 
aspirin or COX-2 inhibitors at the time of registration and they must not have a 
documented allergic reaction or hypersensitivity to them. Aspirin is a non-reversible anti-
platelet drug, which is also contraindicated for patients with bleeding diatheses. Patients 
with bleeding diatheses will also be excluded due to the increased bleeding risk. Patients 
with a history of peptic ulcer disease or gastrointestinal bleeding will be excluded from 
the study due to the increased risk of bleeding seen with NSAIDs, especially aspirin.66,52  
Female participants must not be pregnant or breastfeeding and both sexes must agree 
to use effective contraception for the duration of the study and up to 90 days after the last 
study drug administration.  
Refer to Appendix E for ECOG Performance Status Criteria. Please see Appendix B 





to be equally effective thus there is no specific testing option is recommended by the 
FDA.17 Please see the criteria for TNM staging in Appendix A and the RECIST criteria in 
Appendix K.  
2.4c Dosing Regimen of Nivolumab and Ipilimumab  
The FDA approved dosage of nivolumab and ipilimumab for MSI-H/dMMR CRC is 
nivolumab 3 mg/kg followed by ipilimumab 1 mg/kg on the same day every 3 weeks for 
4 doses, then nivolumab 240 mg every 2 weeks until disease progression or unacceptable 
toxicity. This regimen was determined based on safety data from the CheckMate 142 
trial.4 
FDA dosage recommendations were revised in March 2019 to a non-weight-based 
regimen as follows: Adult and pediatric patients ≥40 kg: 240 mg every 2 weeks or 480 
mg every 4 weeks. Adult and pediatric patients ≥40 kg: 3 mg/kg followed by ipilimumab 
1 mg/kg on the same day every 3 weeks for 4 doses, then 240 mg every 2 weeks or 480 
mg every 4 weeks.67  
The recently revised Opdivo (nivolumab) package insert advises 30 minute infusion 
times, however, in the CheckMate 142 study the drug infusions of nivolumab took place 
over 60 minutes and the infusions of ipilimumab took place over 90 minutes, thus we will 
be using this infusion timeline as well as the dosing regimen to keep study parameters 
identical increase the validity of the cross-trial comparison. 
2.4d Dosing Regimen of Celecoxib  
The fixed dosing regimen of celecoxib was determined based on safety data and the 
intent of providing the highest dosage with tolerable toxicities to avoid sub-therapeutic 
treatment dosages. The 400mg once daily regimen was based on safety data obtained in a 





patients.46 Celecoxib safety is discussed further in Section 2.2g. There will be no dose 
adjustments made to keep study variables consistent.  
2.4e Dosing Regimen of Aspirin  
As the highest dose of aspirin that is effective in producing a synergistic effect with 
ICIs is not known, the dose of aspirin was also determined based on safety data. Our 
intent was to use the highest tolerable dose to avoid subtherapeutic dosages. We will use 
the 325mg daily dose based on safety data discussed in Section 2.2g. No dose 
adjustments will be made to keep study variables constant.  
2.4f Intervention 
The intervention consists of celecoxib or aspirin that will be administered in addition 
to the nivolumab plus low dose ipilimumab combination. The timing, mode of 
administration and dose of nivolumab and ipilimumab will be modeled after the 
CheckMate 142 trial to ensure increased validity of the cross-trial comparison. The 
celecoxib and aspirin doses were determined based on safety studies referenced in 
Section 2.4d and 2.4e as there are no safety or efficacy data from clinical trials regarding 
the combination of COX inhibitors and ICIs.  
2.4g Primary Outcome Measures 
The primary outcome measure will be objective response rates (ORR) radiologically 
examined and evaluated by the RECIST v1.1 criteria.  
Refer to SUPPLEMENT Q for definitions of outcome measures as per RECIST v1.1. 
This outcome measure was chosen to match the CheckMate 142 trial to ensure the 
validity of the cross-trial comparison. 
2.4h Secondary Outcome Measures 
The secondary outcome measures were also chosen to match the secondary 





independent central review (BCIR) ORR and PFS, as our study is a single center study 
and does not require central review. Secondary endpoints are disease control rate (DCR), 
progression free survival (PFS), overall survival (OS), safety and tolerability, association 
between biomarker expression (BRAF mutation status, KRAS mutation status, PD-L1 
expression, clinical history of Lynch syndrome) and efficacy and changes from baseline 
in patient reported outcomes (PRO).  
The patient reported outcomes (PRO) will consists of two questionnaires. These 
will be conducted at baseline, and at every 6 weeks based on the European Organisation 
for Research and Treatment of Cancer (EORTC) Core Quality of Life Questionnaire 
(QLQ-C30) and three-level five-dimensional EuroQol instrument (EQ-5D). The EORTC 
QLQ-C30 has three components: symptoms, functioning and quality of life (QOL). The 
EuroQol instrument is a non-disease specific questionnaire that is intended to 
complement the QLQ-C30 that was designed to evaluate quality of life measures in 
patients participating in clinical studies.68,69,70 
2.4i Other Variables 
Although there are no validated independent prognostic predictors of survival or 
response specifically in MSS mCRC regarding ICI treatment, there are several promising 
emerging biomarkers such as Immunoscore and MDSC level.  
Immunoscore is a novel cancer classification system with a focus on immune 
infiltration in the tumor microenvironment. The Immunoscore system sums up the 
density of CD3+ and CD8+ T-cell effectors both within the tumor and within the invasive 
margin, scored 0 (no T-cell effectors in either tumor or invasive margin) to I4 (T-cell 





There is accumulating evidence that Immunoscore could be predictive of ICI efficacy 
in both the MSS and MSI-H populations. In fact, a multivariate analysis showed that 
Immunoscore is a stronger predictor of patient survival and disease specific recurrence 
than microsatellite instability.71  
 An international consortium conducted a study to assess the prognostic value of 
Immunoscore found that in TNM stage I-III colorectal cancer, Immunoscore association 
for time to recurrence was independent of patient age, sex, T stage, N stage, 
microsatellite stability and other existing prognostic factors studied.21 The study that 
examined tissue samples from 3539 patients also found significant positive correlation 
between densities of CD3+ and CD8+ tumor cells and survival and negative correlation 
with the risk of recurrence. The difference in risk of recurrence reported as hazard ratio 
(HR) in high vs. low Immunosocre was 0.20, (95% CI 0.10-0.38; p<0.00010) translating 
to an 80% reduction in recurrence risk.21 Of significance, 21% of patients with MSS 
colorectal tumors have high Immunoscore21 and about 50% had I3-I4.71 Thus, it is 
possible that Immunoscore could identify a subset of MSS CRC that can be targeted with 
immunotherapies. Altough Immunoscore was found to be a more effective predictor than 
age and sex, the results have not been validated for mCRC (only TNM stage I-III), thus 
age and sex will have to be considered as factors for stratification in the mCRC 
population in our study. 
A negative predictor of survival is MDSC level. Importantly, MDSCs found in the 
blood stream predict higher TNM stage and increased mortality,72 thus it is a useful 
marker of survival. A meta-analysis found cancer mortality doubled upon the detection of 





0.0001) in patients with solid tumors, including CRC.73 Since increased COX-2 
expression leading to increased PGE2 levels may be one mechanism that allows tumor 
cells to evade host immune surveillance through accumulation of myeloid-derived 
suppressor cells (MDSCs) and evasion from T cell–mediated immune attack, we 
anticipate that MDSC level be a better marker of objective response rate than COX-2 
expression level. Thus, instead of COX-2 levels, we will use its downstream effector 
MDSC as a stratum for random allocation.  
Of note, Immunoscore and MDSC level are both hypothesized to be in the CRC 
causal pathway, thus are considered to be mediators rather than confounders.  
Biomarker assessment will include genotyping the oncogenes KRAS, NRAF, BRAF 
(mutated vs. wild type), clinical history of Lynch syndrome, tumor PD-L1 expression 
level, tumor burden and COX-2 expression. We will measure MDSC levels and C-
reactive protein as a novel marker of chronic inflammation, as well as the immune 
suppressive cytokines sTNF, Il-1β, Il-10 and TGF-β. 
The CheckMate 142 trial did not find any association between objective response 
rates in MSI-H/dMMR mCRC and history of Lynch syndrome, BRAF or KRAS mutation 
status or PD-L1 expression status4. These associations, except for no association of 
responses with PD-L1 expression status, were not reported and perhaps would not have 
been statistically meaningful in the small (23 patients) MSS/pMMR population examined 
in their trial. In this study we aim to recruit a larger sample of MSS patients to direct us 
toward more clinically meaningful data on biomarker association with objective response 





2.4j Sample Size and Statistical Significance  
Simon’s two-stage design will be used. The primary objective of phase II trials is to 
determine whether the intervention (here a drug combination) has sufficient activity 
against a disease state, which here is MSS mCRC. In a traditional single stage study 
design, this determination could take months or years, exposing patients to treatments 
that might have no benefit for them, and might even expose them to undue risk. The goal 
of the Simon’s two-stage design is to minimize sample size in case the intervention has 
low or no activity.74  
In the first stage, 14 patients will be enrolled. If there are 1 or fewer responses in 
these 14 patients, the study will be stopped. Otherwise, 27 additional patients will be 
enrolled for a total of 41. The null hypothesis will be rejected if 7 or more responses are 
observed in 41 patients. This design yields a type I error rate of 5% when the true 
response rate is 23.7%. Refer to Appendix N for more information.  
2.5 CONCLUSION 
Several lines of evidence have shown that the combination of checkpoint inhibition 
and COX-2 inhibition act synergistically to reduce tumor promoting inflammation and 
increase immunogenicity in the tumor environment. The success of checkpoint inhibition 
via the combination of PD-1 blockade and COX-2 inhibition in preclinical studies using 
murine and human in vitro models suggests a possible role for this combination therapy 
in the treatment of mCRC in the clinic. The association of lower PD-L1 expression and 
survival in post hoc analysis of large prospective cohort studies further strengthens the 
case for the addition of COX inhibitors as an immunomodulatory agent to ICIs for the 








KRAS: Kirsten Rat Sarcoma gene. Oncogene that normally controls cell proliferation. 
Mutated KRAS confers unchecked cell proliferation.  
NRAS: Neuroblastoma Rat Sarcoma gene, proto-oncogene.  
BRAF: Murine oncogene viral sarcoma Homolog B, a proto-oncogene  
Interferon ϒ+   A cytokine that functions in immune processes 
Tregs Tumor-infiltrating regulatory T-cells  
Interleukin 6,8 and 1 tumor promoting cytokines 
CTLs Cytotoxic T lymphocytes, lymphocytes responsible for attacking viral invaders and 
cancer cells or other damaged cells 
CD247 A gene that encodes programmed death ligand one (PD-L1) 
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CHAPTER 3: STUDY METHODS  
3.1 STUDY DESIGN 
The proposed study will be a single center, open label, randomized allocation, parallel 
assignment, Stage II clinical trial investigating the effects of nivolumab/ipilimumab plus 
celecoxib or aspirin in patients with MSS/pMMR mCRC compared to a historical control 
of nivolumab/ipilimumab alone in MSS/pMMR mCRC arm of the CheckMate 142 trial. 
Assignment to the celecoxib or aspirin treatment group will be determined by random 
assignment. We will also follow the biomarkers BRAF/KRAS/NRAS mutation status (at 
baseline), PD-L1 expression, IDO1 expression, MDSC level and COX-2 expression 
level, cytokines Il-6 and Il-1β evaluated at baseline and at the follow up biopsy.  
3.1a Study Groups  
Our interventional groups consist of patients who are ≥ 18 years of age and have 
mCRC that is histologically confirmed as MSS or pMMR mCRC, evaluated by local 
guidelines. (See Appendix B for MSI criteria evaluation options.) These patients either 
have progressed on or were intolerant of previous treatment with cytotoxic chemotherapy 
with irinotecan, fluorouracil and oxaliplatin. Patients who declined systemic 
chemotherapy are also eligible. Patients are permitted to have participated in curative-
intent or palliative radiation therapy, chemotherapy, biological therapy or other 
investigational therapy but all therapies must be completed by >28 days before treatment 
initiation and all palliative radiation treatments must be completed ≥ two weeks before 
treatment initiation. All patients must have an Eastern Cooperative Oncology Group 
(ECOG) performance status of ≤ 1 and measurable disease per Response Evaluation 
Criteria in Solid Tumors (RECIST version 1.1).  See Appendix E for ECOG performance 





Exclusion criteria includes any active, known or suspected autoimmune disease, 
requiring corticosteroid treatment >10mg prednisone daily or other immunosuppressive 
medication ≤ 14 days prior to beginning treatment. Patients with prior treatment with the 
anti-PD1, anti-PD L1/L2 and anti CTL-4 immune checkpoint or other agent targeting T-
cell co-stimulation or immune checkpoint pathways are excluded.  
Also excluded are patients with serious uncontrolled medical disorders. Patients with 
active brain or leptomeningeal metastases or prior malignancy within the previous 3 years 
except for cured select localized cancer are also excluded from the study.  
Patients must not be taking Non-steroidal Anti-inflammatory Drugs (NSAIDs), 
Aspirin or COX-2 inhibitors at the time of registration and they must not have a 
documented allergic reaction or hypersensitivity to them. Patients with a history of peptic 
ulcer disease or GI bleeding are excluded. Patients with bleeding coagulopathies, such as 
Von Willebrand disease, liver failure, antiphospholipid syndrome, glucose-6 phosphate 
dehydrogenase (G6PD) deficiency, and hemophilias will be excluded from the study. 
Female participants must not be pregnant or breastfeeding and both sexes must agree 
to use effective contraception for the duration of the study and up to 90 days after the last 
study drug administration. 
3.1b Treatment Administration  
Nivolumab will be dosed at 3mg/kg IV, administered over 60minutes followed by 
ipilimumab 1mg/kg IV infusion administered over 90minutes once every 3 weeks for 
four doses and then nivolumab 3mg/kg IV once every 2 weeks until disease progression, 
discontinuation because of toxicity, death, withdrawal of consent, or study end. No dose 
modifications are permitted. See Appendix H for Nivolumab and Ipilimumab dose 





permitted and documented. See Appendix M for Criteria for Treatment Delay and 
Resumption. Treatment beyond the initial progression will be permitted if the patient 
tolerates and deemed to benefit from the study treatment at the investigator’s discretion.4  
3.2 PATIENT SELECTION AND STUDY POPULATION 
The source population includes adults of at least 18 years of age with previously 
treated microsatellite stable (MSS) mCRC. The study population is drawn from this pool 
over a 6-month enrollment period at Yale New Haven Hospital. All participants must 
have a completed eligibility criteria checklist (Appendix F Eligibility Criteria Checklist). 
The eligibility criteria are described in detail in Section 3.1. After confirmation of 
eligibility, signing of the Consent for Participation in the Research Project (Appendix G) 
by both the patient and the investigator and completing the Patient Registration Form 
(Appendix I), the patients will be assigned an identifying number (Patient Registration 
Number) by a regulatory staff member. This identifying number will be recorded on 
every document in addition to the patient’s name and serve as a patient identifier.  
3.3 STUDY REGULATION AND SUBJECT CONFIDENTIALITY 
Yale cancer trials are sponsored by the National Cancer Institute (NCI) and follow 
NCI guidelines outlined in the Investigator’s Handbook.75 The protocol application along 
with the Compound Authorization and Consent for Participation in a Research Study 
form (Appendix G) will be submitted to the Yale Institutional Review Board (IRB). All 
study personnel will obtain Health Insurance Portability and Accountability Act (HIPAA) 
certification prior to the beginning of recruitment. Research staff must also complete the 
Yale HIC training. Although all four drugs used in the trial are commercially available, 
because they are used off label, the study will be required to file the investigational new 





the Yale Human Investigation Committee (HIC). The study will be conducted in 
accordance with the Declaration of Helsinki and Good Clinical Practice guidelines, and 
the informed consent form that explains the study in an easily understandable language 
will be supplied to eligible participants.  
3.4 RECRUITMENT  
Study participants will be recruited from the pool of patients undergoing treatment for 
mCRC at Yale Cancer Center (YCC), which is a National Cancer Institute (NCI) 
designated comprehensive cancer center in Southern Connecticut. YCC is a collaboration 
between nationally and internationally renowned researchers, physicians, physician 
assistants, nurse practitioners and medical staff at the Yale School of Medicine and 
Smilow Cancer Hospital. Participants will be recruited from the YCC group sites over a 6 
months period via flyers and advertisements placed on clinical trial websites.  
3.5 STUDY VARIABLES AND MEASURES 
The independent variables of the study are the drug regimen used in the two arms of 
the study. Arm A will be given ipilimumab 1mg/kg IV, nivolumab 3mg.kg IV and aspirin 
325mg daily orally, while Arm B will be given ipilimumab 1mg/kg IV, nivolumab 
3mg/kg IV and celecoxib 400mg daily orally. The dependent variable examined as the 
primary outcome is objective response rate (ORR). ORR is defined as best response or 
complete response (CR) or partial response (PR) divided by the number of treated 
patients as per RECIST v1.1 guideline. To determine the ORR, tumor burden will be 
measured at baseline and throughout the treatment period. Secondary endpoints 
(dependent variables) were disease control rate (DCR), safety and tolerability, 
progression free survival (PFS), overall survival (OS), association between biomarker 





cytokine Il-1β and Il-6 expression) and efficacy (ORR, PFS, OS) and changes from 
baseline in patient reported outcomes (PRO). Secondary outcome measures will also be 
measured at baseline and followed throughout the study, as discussed in Section 3.7.  
3.6 METHODOLOGY CONSIDERATIONS 
 
3.6a Assignment of intervention 
Upon the completion of the eligibility checklist and registration form, the patients 
will be randomly assigned using permuted block randomization to either study Arm A or 
B of by a statistician. Neither patients, nor research staff will be blinded to allocation. 
3.6b Adherence 
Adherence will be monitored and recorded throughout the duration of the study. 
Study medications administered by the treatment team such as nivolumab and 
ipilimumab infusions will be logged at each visit. Patients will be reminded of infusion 
appointments via telephone 24 hours prior to the appointment time and will require a 
verbal confirmation. Patients will be given the oral medications in study issued bubble-
packaging with dates for each dose and patients will be required to return the empty 
packaging at the subsequent appointment time. Adherence to oral medication will be 
logged by Research Staff.   
3.6c Monitoring of Adverse Events  
All adverse events (AEs) will be reported to the Yale IRB at the time of the 
continuing review. Serious adverse events (SAE) will be reported to the Yale IRB within 
5 business days using the Form 710 FR4: UPIRSO, Including AEs Reporting Form 
through the Yale IRES (See Appendix Q for definitions of AE and SAE).76 
Adverse events will be further analyzed based on the published in-depth safety 
evaluation of the CheckMate 142 trial24 and will include frequency of treatment related 





incidences, time to onset (TTO), time to resolution (TTR), immune modulating 
medication (IMM) use, dose delay, and sTRAE occurrence after resuming therapy. Refer 
to Appendix N for definitions of TRAE and IMAE (Immune mediated adverse events). 
3.7 DATA COLLECTION  
Efficacy and safety data will be collected on any patient who received at least one 
treatment dose. The data will be collected by the study Research Staff and by 
administrative staff at Smilow Cancer Hospital at Yale. Subjects will be enrolled during a 
six months enrollment period and the data collection phase will take 18 months for the 
total study duration of two years.  
Tumor burden will be measured at baseline using computed tomography (CT) or 
magnetic resonance imaging (MRI) evaluated by the RECIST criteria (Version 1.1) ≤ 28 
days before the first dose (Treatment Start Date). Subsequent assessments will be carried 
out every 6 weeks for 24 weeks and every 12 weeks thereafter until either disease 
progression or discontinuation. All responses will need to be confirmed by a second scan 
≥ 4 weeks later. The primary endpoint of objective response rate (ORR) will be based on 
these imaging studies. Patients will be observed for survival every three months up to the 
two-year mark of the study to evaluate the secondary endpoint of overall survival (OS). 
Patient reported outcome (PRO) analyses will be conducted at baseline, and at every 
6 weeks based on the European Organisation for Research and Treatment of Cancer 
(EORTC) Core Quality of Life Questionnaire (QLQ-C30) and three-level five-
dimensional EuroQol instrument (EQ-5D).69, 68 
The EORTC QLQ-C30 has three components: symptoms, functioning and quality of 





and 0 corresponding to the worst functioning. For each of these scales an at least 10-point 
change from baseline was deemed clinically meaningful.70 
The EQ-5D will analyze problems in five health dimensions: mobility, self-care, 
usual activities, pain or discomfort, and anxiety or depression and will rate them on a 
scale of “None”, “Some” or “Extreme”. We will also utilize the EQ-5D visual analog 
scale that patient will use to rate their health on a scale of 0-100, with higher values 
corresponding to better health. An at least 7-point change from baseline will be regarded 
as clinically meaningful.  
Participants will be assessed for signs and symptoms of ICI related adverse events 
and blood samples will be collected at baseline and before each ICI dose to evaluate 
clinical chemistries including liver function tests (LFTs), adrenocorticotropic hormone 
(ACTH) level, and thyroid function tests.  
Tissue samples will be collected from all participants. Patients will be able to provide 
data from a previous biopsy to determine the baseline biomarker status but a second 
sample will be collected to determine changes from baseline. Tissue samples will be 
collected according to the Yale IRB Policy 440: Collection and Banking of Data, 
Biological Specimens and Other Materials in Human Research.77 
Safety will be evaluated using the Common Terminology Criteria for Adverse Events 
(CTCAE Version 5.0 See Appendix D) throughout the duration of the treatment.50  
3.8 SAMPLE SIZE CALCULATION  
Simon’s two-stage design will be used.74 The null hypothesis that the true 
response rate is 8.7% observed in the CheckMate 142 trial will be tested against two one-
sided alternatives. In the first stage, 14 patients will be enrolled. If there are 1 or fewer 





patients will be enrolled for a total of 41. The null hypothesis will be rejected if 7 or more 
responses are observed in 41 patients. This design yields a type I error rate of 5% when 
the true response rate is 23.7%. See Appendix J for additional calculations.  
3.9 ANALYSIS 
 Data analysis will be modeled after the CheckMate 142 trial. The baseline 
demographics data such as age, sex, race, ECOG performance status, primary tumor 
location, number of prior systemic treatments, prior therapies received, prior radiotherapy 
received, mutation status (BRAF/KRAS wild type, BRAF mutation, KRAS mutation, 
unknown), tumor PD-L1 expression quantifiable at baseline and clinical history of Lynch 
syndrome of the study sample will be described and compared by treatment group and 
historical control group. The data will be reported using descriptive statistics with 
standard deviation and means, medians and ranges for continuous variables.   
 Data from all enrolled patients will be analyzed regarding efficacy and safety. The 
secondary outcomes of safety and tolerability and patient reported outcomes (PRO) will 
also be measured using descriptive statistics. The 95% CI for the dichotomous measure of 
objective response rates (ORR) will be estimated using the Clopper and Pearson method. 
ORR (proportion of patients with a predefined amount of tumor reduction) in the two 
treatment arms will be compared using the chi-square test. If the observations are rare, 
Fisher Exact Test will be used. The Kaplan-Meier product-limit method will be used to 
determine medians for time to event measures such as progression-free survival (PFS), 
overall survival (OS), duration of response (DOR) and the corresponding 95% CI will be 
calculated based on log-log transformation.  
The primary outcomes of objective response rate (ORR) and the secondary 





(OS) will be measured based on the RECIST v1.1 guideline. Data will be analyzed based 
on the per protocol analysis. We will consider P-values less than 0.05 as statistically 
significant for all analyses.  
3.10 TIMELINE AND RESOURCES  
The study time period is planned to be 24 months, with a 6-month period of rolling 
enrollment followed by 18 months of treatment administration. Statistical analysis or 
objective response rate will be performed on a rolling basis, but majority of the data 
analysis will take place after the conclusion of the treatment of the last participant.  
The full-time study personnel will include the principal investigator (PI), Dr. Michael 
Hurwitz, Co-PI, Angela Preda, PA-SII, Research Staff (administrative) who will be 
tasked with patient recruitment, data collection, and data entry. The study will seek to 
recruit part time pathologist to assist with analysis of tumor samples and a statistician to 
aid with data analysis. Standard oncological care will be provided by the patients’ 
oncologist at Yale New Haven Hospital who will have frequent communication with the 
study research personnel. All clinical tasks such as phlebotomy, imaging and laboratory 
analysis will be performed by hospital resources.  
The full-time personnel will require office space in the Oncology Department at Yale 
New Haven Hospital equipped with a computer with appropriate software for statistics, 
data storage and analysis.  
The study drugs ipilimumab and nivolumab will be supplied by Bristol-Myers Squibb 
and Celebrex will be supplied by Pfizer Inc. No other resources will be utilized from 
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CHAPTER 4: CONCLUSION  
4.1 Study Advantages 
 Although our Phase II study sample is smaller than a Phase III trial’s, we aimed to 
reduce the effect of confounders by the randomization of subjects into the two arms. 
The use of a cross-trial control arm intended to reduce potential harm to subjects 
by eliminating randomization to an arm with suboptimal response rates and response 
durations. This trial design also reduced the number of subjects need to be recruited. 
The Simon’s two-stage design introduces an element of safety as the trial will only go 
to second stage if there are adequate number of responding patients. This practice avoids 
exposing patients to undue risk in case the intervention has low or no activity. 
The relative ease of recruitment is another advantage. The low prevalence of the MSI-
H mCRC forced the CheckMate 142 trial to be carried out as a multi-center study. With 
96% of mCRC being MSS,6 our study anticipates greater ease in recruiting. Given the 
21% prevalence of mCRC is in the CRC population, the MSS mCRC portion of all CRC 
patients presenting is about 20%. Thus, theoretically, one fifth of all Yale New Haven 
Hospital CRC patients are eligible to participate.  
4.2 Study Limitations 
 
To reduce the possibility of confounders, we used restriction and randomization 
during the design phase of the study while also keeping the external validity in mind.  
The study has moderately permissive exclusion criteria, a practice that could lend 
itself to introduction of confounders. For example, previous treatment with biological or 
other investigational treatments were not a reason for exclusion. As we are uncertain of 





Although more strict restriction would have increased internal validity, it would have 
decreased the external validity and generalizability.  
Comparing the treatment arms to a historical control can also present as a drawback 
since we are comparing patient populations at different institutions. For the measure of 
the effect, namely objective response rate (ORR) we modeled our trial after the 
CheckMate 142 study’s arm that recruited non-MSI-H mCRC patients (MSS). This arm 
of the study was rather modest, recruiting only 23 patients but showed an ORR of 8.7% 
(2 responses in 23 patients). Demographics and biomarker data (except for PD-L1) was 
not reported for this cohort, thus we will not be able to compare the control arm and our 
experimental arms regarding these variables.  
While our study is designed to run for 18 months, follow up of disease recurrence at 
later time points is crucial. Our 18-month study duration will be sufficient for elucidating 
responses and immediate adverse events but it is essential that patients will be followed 
for a longer period of time to measure long-term effects of these drugs.  
Another limitation of our study is that although it permits the participation of patients 
who decline the use of cytotoxic chemotherapy, the majority of patients will have had 
previous treatment with one or more first or second line agents. To recruit sufficient 
number of patients in a single center setting, we cannot restrict this variable. However, 
the response rates might be increased in treatment naïve patients.  
4.3 Clinical Significance  
This trial aims provide an ICI option to the MSS subgroup, which currently relies on 
traditional cytotoxic chemotherapy. Thus, an immune therapy option for this population 
would signify a paradigm shift. We also anticipate gaining insight into the biomarkers 








6. Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts 
response of solid tumors to PD-1 blockade. Science (New York, N.Y.). 
2017;357(6349):409-413. 










APPENDIX A TNM STAGING OF COLORECTAL CANCER 
 
 
General Definition of Colorectal Cancer:  
Adenocarcinoma, high-grade neuroendocrine carcinoma and squamous carcinoma of the 
colon and rectum are covered by this staging system  
 
Excluded are appendiceal carcinoma, anal carcinoma and well-differentiated 




Stage 0:  Tis  N0  M0  
Stage I:  T1 - T2  N0  M0  
Stage IIA:  T3  N0  M0  
Stage IIB:  T4a  N0  M0  
Stage IIC:  T4b  N0  M0  
Stage IIIA:  T1 - T2  N1 / N1c  M0  
 T1  N2a  M0  
Stage IIIB:  T3 - T4a  N1 / N1c  M0  
 T2 - T3  N2a  M0  
 T1 - T2  N2b  M0  
Stage IIIC:  T4a  N2a  M0  
 T3 - T4a  N2b  M0  
 T4b  N1 - N2  M0  
Stage IVA:  any T  any N  M1a  
Stage IVB:  any T  any N  M1b  
Stage IVC:  any T  any N  M1c  
 
 
Primary tumor (pT) 
• TX: primary tumor cannot be assessed  
• T0: no evidence of primary tumor  
• Tis: carcinoma in situ, intramucosal carcinoma (involvement of lamina propria 
with no extension through muscularis mucosae)  
• T1: tumor invades submucosa (through the muscularis mucosa but not into the 
muscularis propria)  
• T2: tumor invades muscularis propria  
• T3: tumor invades through the muscularis propria into the pericolorectal tissues  





o T4a: tumor invades through the visceral peritoneum (including gross 
perforation of the bowel through tumor and continuous invasion of tumor 
through areas of inflammation to the surface of the visceral peritoneum)  
o T4b: tumor directly invades or adheres to other adjacent organs or 
structures  
 
Regional lymph nodes (pN) 
• NX: regional lymph nodes cannot be assessed  
• N0: no regional lymph node metastasis  
• N1: metastasis in 1 - 3 regional lymph nodes  
o N1a: metastasis in 1 regional lymph node  
o N1b: metastasis in 2 - 3 regional lymph nodes  
o N1c: no regional lymph nodes are positive but there are tumor deposits in 
the subserosa, mesentery or nonperitonealized pericolic or perirectal / 
mesorectal tissues  
• N2: metastasis in 4 or more regional lymph nodes  
o N2a: metastasis in 4 - 6 regional lymph nodes  
o N2b: metastasis in 7 or more regional lymph nodes  
 
 
Distant metastasis (pM) 
• M0: no distant metastasis by imaging; no evidence of tumor in other sites or 
organs (this category is NOT assigned by pathologists)  
• M1: distant metastasis  
o M1a: metastasis confined to 1 organ or site without peritoneal metastasis  
o M1b: metastasis to 2 or more sites or organs is identified without 
peritoneal metastasis  
o M1c: metastasis to the peritoneal surface is identified alone or with other 





Weisenberg E. TNM staging of colorectal carcinoma (AJCC 8th edition). 
PathologyOutlines.com website. 
http://www.pathologyoutlines.com/topic/colontumorstaging8ed.html. Accessed July 13th, 
2019. 
 
APPENDIX B MICROSATELLITE INSTABILITY CLASSIFICATION 
 
 
Testing for microsatellite instability in CRC can be accomplished via three methods: 
1. Immunohistochemical staining for the complete loss of the four most common 
mismatch repair (MMR) proteins: MLH1, MLH2, MSH6 and PMS2.  
2. Testing the length of five specific microsatellites (BAT25, BAT26, D2S123, 





conferred to tumor samples with instability (defined as length variation between 
normal and tumor samples)in greater than 30% of microsatellites.  
3. MSIsensor which is a next-generation sequencing that evaluates a large number of 
microsatellites throughout the genome.  
 




Overman MJ, Ernstoff MS, Morse MA. Where We Stand With Immunotherapy in 
Colorectal Cancer: Deficient Mismatch Repair, Proficient Mismatch Repair, and Toxicity 
Management. American Society of Clinical Oncology educational book. American 
Society of Clinical Oncology. Annual Meeting. 2018(38):239-247. 
 
 
APPENDIX C IMMUNOSCORE 
 
 
Quantitative immunohistochemistry to determine te density of CD3+ and CD8+ cells (as 
markers of TH1/cytotoxic memory T lymphocytes CD8 and CD45RO) in CRC tumors. 
Immunohistochemistry staining of CD3+ and CD8+ is performed in two regions, CT 
(center of tumor) and IM (invasive margin) and is followed by automated quantification 
of whole slide sections. The Immunoscore utilizes the numeration of cells in the 
CT and the IM of resected tumors to provide a score ranging from 0-4, Immunoscore 0 
(“I” 0), when low densities of both cell types are found in both regions, to Immunoscore 
4 (“I” 4), when high densities are found in both regions. 
 
I 0  –   –   –   – 
I 1 Hi  –   –   –  
I 2 Hi Hi  –   –  
I 3 Hi Hi Hi  – 
I 4 Hi Hi Hi Hi  
 
Current Immunoscore procedure and reagents 
Procedure  Current recommended steps 
Tumor selection Block which is the most infiltrated by the immune cells and 
containing the core of the tumor (CT) and the invasive margin 
(IM) 
Sample preparation  2 paraffin sections of 4-microns of the tumor block deposited in 
deionized water on Superfrost-plus slides 
Immuno- 
histochemistry (IHC) 2 single stainings using IVD certified antibodies 
Antigen retrieval CC1 tris-based buffer pH8 
Primary antibody CD3 (2GV6, Ventana) and CD8 (C8/144, Dako) 
Primary antibody 





Secondary reagents  Ultraview TM DAB (Ventana) 
Counterstaining Hematoxillin II (Ventana) 
Autostrainer  Benchmark XT (Ventana) 
Scanner  NanoZoomer 2.0-HT (Hammamatsu) 
Digital pathology Architect XD software (Definiens) 
Immunoscore 
Quantification  Immunoscore Plug-in (INSERM / AP-HP) 
 
Reference: 
Galon J, Pagès F, Marincola FM, et al. Cancer classification using the Immunoscore: a 
worldwide task force. Journal of translational medicine. 2012;10(1):205. 
 
 
APPENDIX D NATIONAL CANCER INSTITUTE COMMON 




Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; 
intervention not indicated.  
Grade 2 
Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate 
instrumental ADL*.  
Grade 3 
Severe or medically significant but not immediately life-threatening; hospitalization or 
prolongation of hospitalization indicated; disabling; limiting self care ADL**.  
Grade 4 
Life-threatening consequences; urgent intervention indicated.  
Grade 5 
Death related to AE.  
 
*Instrumental ADL refers to preparing meals, shopping for groceries or clothes, using the  
telephone, managing money, etc.  
**Self care ADL refers to bathing, dressing and undressing, feeding self, using the toilet, 




National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) 
v5.0  
https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Q








APPENDIX E ECOG PERFORMANCE STATUS SCALE 
 
GRADE  
0 Fully active, able to carry on all pre-disease performance without restriction 
1 
Restricted in physically strenuous activity but ambulatory and able to carry out 
work of a light or sedentary nature, e.g., light house work, office work 
2 
Ambulatory and capable of all self-care but unable to carry out any work 
activities; up and about more than 50% of waking hours 
3 
Capable of only limited self-care; confined to bed or chair more than 50% of 
waking hours 
4 






Oken M, Creech R, Tormey D, et al. Toxicity and response criteria of the Eastern 
Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649-655. 
 
APPENDIX F ELIGIBILITY CHECKLIST 
 
The following form must be filled out completely and must be signed by both the patient 
and the provider. Patients must meet all criteria to be eligible for this study.  
 
Proposed treatment start date: _______________ 
 
1. ☐ Age ≥ 18 years of age. DOB _____________  Today’s date: _____________ 
2. ☐ Recurrent CRC or mCRC. Histologic confirmation _____________________ 
Sites of metastases__________________________________________________ 
3. ☐ No active brain or leptomeningeal metastases or prior malignancy within the 
previous 3 years except for cured select localized cancer 
4. ☐ Histologically confirmed MSS or pMMR ☐  Histochemistry  or ☐  PCR or 
         ☐  MSIsensor  Date performed _______________ 
5.   ☐ Use of previous chemotherapy regimens of irinotecan, fluoroacil or oxaliplatin 
or refused chemotherapeutic agents 
6.   ☐ Completed curative-intent radiation therapy, chemotherapy, biological or other 
investigational treatment > 28 days before treatment start date 
7.   ☐ Completed palliative radiation therapy ≥ two weeks before treatment start date 
8.   ☐ ECOG Performance Status 0 or 1  





10. ☐ No active autoimmune disease or other disease requiring high dose 
immunosuppression 
11. ☐ No prior treatment with anti PD-1, anti-PD-L1/2 or anti-CTLA-4 immune 
checkpoint agent or other agent targeting T-cell co-stimulation or immune checkpoint 
pathways 
12. ☐ No serious uncontrolled medical disorder  
13. ☐ Not taking NSAIDs, aspirin or COX-2 inhibitors at the time of the registration.  
14. ☐ No documented allergic reaction or hypersensitivity to COX-2 inhibitors, 
aspirin or NSAIDs 
15. ☐ No history of peptic ulcers or gastrointestinal bleeding  
16. ☐ No bleeding diathesis  
      17. ☐ Absolute leukocyte count ≥2500 /mcL 
     18. ☐ Absolute lymphocyte count (ALC) ≥500 /mcL 
     19. ☐ Absolute neutrophil count (ANC) ≥1500 /mcL 
     20. ☐ Platelets ≥100,000 / mcL 
     21. ☐ Hemoglobin 
≥9 g/dL or ≥ 5.6 mmol/L without 
transfusion or EPO dependency (within 
7 days of assessment) 
 
 22. ☐ No asthma exacerbated by aspirin or NSAID use 
 23. ☐No acute or severe hepatic failure  
       24. ☐Serum total bilirubin ≤ 1.5 X ULN 
             or or 
             ☐Direct bilirubin 
≤ ULN for subjects with total bilirubin 
levels > 1.5 ULN 
       26. ☐AST and ALT  
≤ 2.5 X ULN OR 
≤ 5 X ULN for subjects with liver 
metastases 
       27. ☐Albumin 
> 2.5 mg/dL 
 
 28. ☐ No acute or severe renal failure 
29. ☐Serum creatinine ≤1.5 X upper limit of normal (ULN) 
or or 
Measured or calculated 
creatinine clearance 
(GFR can also be used in place 
of creatinine or CrCl) 
≥60 mL/min for subject with creatinine levels > 1.5 X 
institutional ULN 
 







Women only:  
31. ☐ Not pregnant or breastfeeding determined by β-Hcg level 72 hours prior 








☐ All criteria met.  
 
 
______________________________ Date: __/__/____ 
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COMPOUND AUTHORIZATION AND CONSENT FOR PARTICIPATION IN A 
RESEARCH STUDY 
 
YALE UNIVERSITY SCHOOL OF MEDICINE 
YALE-NEW HAVEN HOSPITAL 




Study Title: Checkpoint and Cyclooxygenase Inhibition in Microsatellite Stable 
Metastatic Colorectal Cancer 
Principal Investigator (the person who is responsible for this research):  
Dr. Michael Hurwitz, MD, PhD 20 York Street, New Haven, CT, 06510 
Phone Number: (203) 400-4822 
 
Research Study Summary: 
We are asking you to join a research study. 
• The purpose of this research study is to investigate how effective and how safe is a 
new drug combination for the treatment of metastatic colorectal cancer.  
• Study procedures will include: a screening visit, physical examination, blood testing, 
biopsy of metastatic tumor site, CT or MRI imaging studies, infusion of 
immunotherapy drugs and a medication taken by mouth. 
• The number of visits required cannot be determined in advance. You will be required 





be receiving a dual immunotherapy infusion every three weeks for the total of four 
doses followed by only one of the drug infusions every other week until we determine 
that your cancer is not responding or you need to discontinue the treatment for 
another reason.  
• These visits will take between 1- and 3.5-hours total.  
• There are some risks from participating in this study. You may experience side 
effects that can range from uncomfortable to serious and can even lead to death 
while taking the study medications.  
• The study may have no benefits to you. As the effectiveness of combination of 
medications was not previously studied, we cannot tell if you will personally benefit 
from participating in this study.  
• There are other choices available to you outside of this research. You may opt for 
the standard of care treatment prescribed by your oncologist, participating in another 
study or seek comfort measures only. 
• Taking part in this study is your choice. You can choose to take part, or you can 
choose not to take part in this study.  You can also change your mind at any time.  
Whatever choice you make, you will not lose access to your medical care or give up 
any legal rights or benefits.  
• If you are interested in learning more about the study, please continue reading, or 
have someone read to you, the rest of this document. Take as much time as you 
need before you make your decision. Ask the study staff questions about anything 
you do not understand. Once you understand the study, we will ask you if you wish 
to participate; if so, you will have to sign this form. 
 
 
Why is this study being offered to me? 
We are asking you to take part in a research study because you are an adult ≥ 18 years 
of age who has been diagnosed with colorectal cancer that has spread to distant sites 
(metastasized). 
We are looking for 82 participants to be part of this research study that will take place at 
Smilow Cancer Hospital at Yale New Haven Hospital.  
 
Who is paying for the study? 
This study is funded by the National Institute of Health (NIH).  
 
Who is providing other support for the study? 
Study medications ipilimumab (Yervoy) and nivolumab (Opdivo) were the generous gift 
of Bristol-Myers Squibb. Celecoxib (Celebrex) was the generous gift of Pfizer.  
 
What is the study about?  
The purpose of this study is to investigate the effects of the combination of three drugs in 
two separate groups, either nivolumab, ipilimumab and celecoxib or nivolumab, 
ipilimumab and aspirin on colon cancer that has spread to distant organs (metastatic 
colon cancer). Our study seeks to investigate whether either of these combinations are 
more effective in the treatment of metastatic colorectal cancer than nivolumab and 
ipilimumab alone. We also seek to investigate the safety of these drug combinations as 
well as find biomarkers (specific markers found in the blood or in a tissue sample) that 







What are you asking me to do and how long will it take?  
If you agree to take part in this study, this is what will happen: In order to determine 
whether your participation in this study is appropriate, you will be asked to complete 
medical screening visit. The testing is routine and can be completed by your medical 
provider in one visit. To be considered eligible to participate in this study, you must be ≥ 
18 years of age and have a diagnosis of colorectal cancer that has spread to distant 
sites but not to the brain or leptomeninges (the covering of the brain). All patients will 
have a magnetic resonance imaging (MRI) to confirm the absence of brain metastases. 
The diagnosis of colorectal cancer and distant spread must be confirmed by a tissue 
sample (histologic diagnosis). You must be able to supply this sample and authorize our 
trial to run tests on this sample. The tests run on this sample or previous testing must 
classify you as microsatellite stable (MSS) and/or proficient mismatch repair (pMMR). If 
no sample is available, you must authorize the study to collect a biopsy sample from an 
available site. If there is no accessible biopsy site available, you will not be eligible to 
participate in the study. Your provider will complete a full medical history to gather 
information about your health, medications and allergies. Your provider will also 
complete a thorough physical examination. You must have normal organ function prior 
to starting this study. Your provider can assess this with routine blood work, which will 
check your blood counts, kidney function and liver function. If any of these routine blood 
tests are not within normal limits, you will not be eligible to participate. As part of the 
blood testing, you will have blood testing for infectious diseases such as Hepatitis B, 
Hepatitis C and HIV. If any of these tests are positive, you will not be able to participate 
in the study.  
 A small blood sample will be taken for routine blood testing for electrolytes, blood 
counts and to measure liver and kidney function and monitor for infection. This routine 
blood testing will be repeated before each ipilimumab dose. 
 You will not be able to participate in this study if you were diagnosed with any 
autoimmune disease that requires you to take more than 10mg of prednisone daily. 
Your provider will determine if you are eligible. Your performance status will be 
assessed and you can only participate if you are fully active or if you are restricted only 
in strenuous activity.  
 You are eligible for this study if you have used chemotherapy of irinotecan, 
fluorouracil or oxaliplatin previously and your cancer did not respond to this treatment or 
if you did not want to use chemotherapy. Prior treatment with any immune checkpoint 
therapy is not permitted. Prior radiation treatment is allowed, but must be completed by 
>28 days before treatment start date and all palliative radiation (not curative intent) 
treatments must be completed ≥ two weeks before treatment initiation. Prior treatment 
with any checkpoint inhibitor is not permitted. 
 If you are a female of childbearing age, you must have documented negative 
pregnancy test within 72 hours prior to the first dose of study medication. This can be a 
blood or urine test and should be done in all women unless you have had your uterus 
removed (hysterectomy) or are postmenopausal (no menstruation in the preceding 12 
months). During the study, both female and male participants must agree to use 
adequate birth control.  
 The size, number and location of your tumors will be assessed using 
computerized tomography (CT) or magnetic resonance imaging (MRI) scan of your 
chest, abdomen and pelvis. You will also have an MRI to check for tumors in your brain. 
Both of these imaging studies will be performed within 28 days of starting study 
protocol. An ECG will be performed to determine heart function. If your provider deems 
necessary, additional imaging might be performed. The information gathered during 





 If you decide to participate in this study and your provider determines that you 
are eligible, you will have additional testing throughout the study period including 
medical history, physical examination and imaging. This additional care is equivalent to 
standard cancer care you would receive if you were not enrolled in the study. 
Computerized tomography (CT) will be performed throughout the study duration to 
monitor for response to the drug regimen and tumor size. CT imaging might be done 
more frequently during the study than you would receive if you received standard care. 
At the beginning of the treatment you will have imaging studies to evaluate tumor size 
every 6 weeks for 24 weeks and every 12 weeks thereafter until either disease 
progression or discontinuation. If you respond to treatment, there will be another 
confirmatory scan ≥ 4 weeks later. 
 A small blood sample will be taken for routine blood testing for electrolytes, blood 
counts and to measure liver and kidney function and monitor for infection throughout 
the study duration. This routine blood testing will be repeated before each ipilimumab 
dose.  
 If you are a female participant, you will be asked for a urine sample for 
pregnancy testing at every visit. Both female and male participants will be asked to use 
adequate birth control method throughout the duration of the study and 3 months after 
the administration of the last dose of nivolumab/ipilimumab. You will be asked to report 
all side effects to your provider as soon as they occur during study duration and up to 3 
months after the administration of the last nivolumab/ ipilimumab dose.  
 This study is planned to run for a total of 18 months. During this trial, you must 
agree not to take other anti-cancer medication (chemotherapy or immunotherapy) or 
supplements that has not been prescribed by your study provider. You also cannot be 
taking immunosuppressant medications, the most common of which is corticosteroids. 
Inhaled and topical forms of corticosteroids are allowed during the trial period.  
 Participants will be randomly assigned to Arm A (nivolumab/ipilimumab plus 
aspirin) or Arm B (nivolumab/ipilimumab plus celecoxib) by study administrators. As a 
participant, you must agree to adhere to the assignment and take the home 
medications as prescribed. Dose adjustment of these medications will not be allowed. If 
dose adjustment is necessary for any reason, you will no longer be able to participate in 
the study. The treatment will begin within 5 business days of randomization.  
If you are in Arm A, you will receive weight-based infusions of nivolumab and 
ipilimumab and a fixed dose of aspirin. If you are in Arm B, you will receive weight-
based infusions of nivolumab and ipilimumab and a fixed dose of celecoxib. You will 
receive nivolumab and ipilimumab every 3 weeks in the beginning for a total of four 
doses followed by nivolumab only infusions every other week. The total number of 
infusions will be decided based on whether you respond to treatment and how well you 
respond to treatment. You might receive the nivolumab infusions until the 18-month 
mark. Each visit to Yale New Haven Hospital will last between 1 and 3 hours and a half 
hours. The doses and allocation to each group are not determined by your clinician and 
cannot be changed once assigned. An equal number of participants will be assigned to 
either arm. Once assigned, you will be required to adhere to the medication regimen in 
the assigned arm. You will be asked to keep a log of the home medication portion of the 
study (aspirin or celecoxib) and bring the log to every appointment. You will also fill out 
two questionnaires in the beginning and every 6 weeks that will ask you about your 
overall wellbeing. These questionnaires generally take about 11 minutes to complete.  
 
What are the risks and discomforts of participating?  
The risks of taking this new drug combination is not yet known, thus there may or may 





used in this study You will be closely monitored during the trial period and you will be 
asked to report any side effects to your provider as soon as they occur. Individually, all 
components of the treatment regimen have been studied and found to have side effects 
that range from mild and manageable to very serious, including a small risk of death. All 
efforts will be made to make you comfortable during the treatment period and treat side 
effects. If the side effects become serious or life threatening, you will receive immune 
suppressant medication that reverses the effect of the study drugs. If you are not able to 
tolerate the drugs, your participation in the study will be stopped. You should seek 
emergency evaluation by calling 911 or going to the Emergency Department in case you 
experience severe side effects to the medications. Most side effects go away once study 
medications are stopped, but there is a chance that side effects become permanent.  
Nivolumab and ipilimumab are FDA-approved biological agents for a group of colorectal 
cancer patients who have the marker called microsatellite instability high (MSI-H) or 
deficient mismatch repair (dMMR) to help the body’s immune respond better in 
eliminating the cancer. This group that does not include the type of cancer that you have 
(Microsatellite stable, MSS), thus the safety information comes mostly from studying the 
other group. Ipilimumab has the highest potential to cause discomforts and risks among 
the study drugs used, but in this study, it is used in what is considered a low dose. 
Patients in previous studies that used this drug combination most commonly 
experienced diarrhea, tiredness and itchiness. About one third of the patients had more 
serious side effects such as elevated liver enzymes, elevated lipase (a pancreatic 
enzyme), low blood counts, and bowel inflammation. About 13 out of 100 patients had to 
discontinue treatment because of serious side effects such as kidney injury or 
autoimmune liver inflammation. Thus, while taking the study medications, there is a 
chance that you will experience some of these side effects. There is a chance that you 
will have to discontinue this study because of the side effects and hospitalization to treat 
the side effects might be necessary.   
 
Celecoxib and aspirin are non-steroidal anti-inflammatory drugs (NSAIDs) that are 
commonly used to treat inflammatory diseases such as arthritis at the dose that is used 
in the study (Aspirin 325mg daily or Celecoxib 400mg daily). Aspirin at a lower dose 
(100mg daily) is also used for colon cancer prevention. Aspirin at the 81mg daily dose is 
also used as an anti-platelet agent to prevent blood clots in the prevention of stroke or 
heart attack.   
 
The most common side effects of aspirin are heartburn, nausea, vomiting and stomach 
pain. Elevated liver enzymes were also reported as well as very rare cases of kidney 
impairment and failure. There is also an increased risk of bleeding. The most serious 
side effects are rare but include bleeding from a stomach ulcer, kidney failure or aspirin-
exacerbated respiratory disease. We take precautions that patients at risk for these 
serious side effects are not participating in this study. The most common side effects of 
celecoxib are dyspepsia, nausea, diarrhea and stomach pain. Side effects will be 
managed by your clinician; however, you might need to discontinue treatment if you 
have a serious bleeding from an ulcer or if your kidney function significantly worsens. 
 
To receive nivolumab and ipilimumab infusions, you will have to have an IV-line placed. 
IV-line placements are common procedures but they can be uncomfortable. Mild pain 
around the IV site is common but goes away quickly when the IV is removed.  
To monitor the progress of your tumors, you will need to have CT or MRI scans 
periodically. CT scans will expose you to a high dose of radiation. Repeated doses of 





radiation but take longer and can be uncomfortable as you must stay still laying on your 
back for long periods of time. If you suffer from claustrophobia, you might not be able to 
tolerate MRI scans.  
 
How will I know about new risks or important information about the study?  
We will tell you if we learn any new information that could change your mind about taking 
part in this study.  
 
How can the study possibly benefit me? 
You may or may not benefit from participating in this trial that will study the benefits and 
potential harms of this new combination therapy. While patients have been taking this 
medication combination previously, the potential benefits and safety of this combination 
have not been previously investigated. Researchers and medical providers think that this 
new combination will be more effective in treating cancer than receiving the two immune 
checkpoint therapy drugs (nivolumab and ipilimumab) alone but it is not known in 
advance who will personally benefit or experience adverse events while taking this 
medication combination.  
 
How can the study possibly benefit other people? 
The benefits to science and other people may include a better understanding of how we 
can make the type of colon cancer patients that you belong to (microsatellite stable, 
MSS) respond to treatment as well as the group these medications are currently FDA 
approved for (MSI-H) and which patients in your group will be good candidates for this 
treatment in the future. We are hoping that the results of this study will lead to new 
treatments for patients with your type of cancer.  
 
Are there any costs to participation?  
If you take part in this study, you will not have to pay for any services, supplies, study 
procedures, or care that are provided for this research only (they are NOT part of your 
routine medical care). The study medications ipilimumab, nivolumab, aspirin or celecoxib 
will be provided to you at no cost. However, there may be additional costs to you. These 
can include costs of transportation and your time to come to the study visits. You or your 
health insurance must pay for services, supplies, procedures, and care that are part of 
your routine medical care.  You will be responsible for any co-payments required by your 
insurance.   
 
Will I be paid for participation?  
You will not be compensated for participating in this study. There is no reimbursement 
for traveling expenses to the study site.  
 
What are my choices if I decide not to take part in this study? 
Instead of participating in this study, you have some other choices.  
You could:  
• The same treatment combination is not available outside of this study for the type 
of colorectal cancer you have (microsatellite stable (MSS) or proficient mismatch 
repair pMMR). You might receive the standard of care treatment decided by you 
and your oncologist. The main treatment options for colorectal cancer that spread 
to distant sites are traditional chemotherapy, anti-VEGF or EGFR therapy. The 
first line chemotherapeutic agents are FOLFOX (folinic acid (leucovorin), 
fluorouracil (5FU) and oxaliplatin), FOLFIRI (folinic acid, 5FU and irinotecan), 





angiogenic agent bevacizumab. For high tumor burden or rapidly progressing 
disease the quadruple chemotherapy FOLFOXIRI (folinic acid, fluorouracil, 
oxaliplatin, irinotecan) can be considered. For refractory colon cancer drugs 
regorafenib or trifluridine/tipiracil are recommended. Some patients in this study 
have already tried these therapies and they didn’t work for them. If you have not 
tried these therapies, you might benefit from trying them. The benefit of 
chemotherapeutic agents is that they are well studied and have known side 
effects. The risk associated with chemotherapy is the uncomfortable and 
sometimes toxic side effects. The side effects of chemotherapy vary based on 
the combination but the most commonly reported are diarrhea, neuropathy 
(numbness and tingling sensation in the arms and legs), fatigue, hair loss and 
cold sensitivity. Some side effects, such as neuropathy can be treatment limiting 
and irreversible. You should further discuss your chemotherapy options with your 
oncologist. 
• Take part in another study. You might also seek to participate in another study 
listed at www.clinicaltrials.gov  
• Receive comfort care only, without any treatment for your disease. This option is 
called palliative care. You and your oncologist may decide what options are best 
for you.  
 
How will you keep my data safe and private? 
We will keep information we collect about you confidential. We will share it with others if 
you agree to it or when we have to do it because U.S. or State law requires it. For 
example, we will tell somebody if you we learn that you are hurting a child or an older 
person. 
Only research staff will have full access to the data we collect about you. Beyond 
registration, the information pertaining to you will only include a registration number and 
will not include any other information that can identify you, such as your name, birthday 
or address. We will store research documents in a locked file cabinet. All research data 
will be stored on a password protected computer.  
When we publish the results of the research or talk about it in conferences, we will not 
use your name. If we want to use your name, we would ask you for your permission. We 
will also share information about you with other researchers for future research but we 
will not use your name or other identifiers.  
Identifiers might be removed from the identifiable private information or identifiable 
biospecimens and that, after such removal, the information or biospecimens (eg. biopsy 
or blood samples) could be used for future research studies or distributed to another 
investigator for future research studies without additional informed consent from the 
subject or the legally authorized representative, if this might be a possibility. We will not 
ask you for any additional permission. 
 
What Information Will You Collect About Me in this Study? 
The information we are asking to use and share is called “Protected Health Information.” 
It is protected by a federal law called the Privacy Rule of the Health Insurance Portability 
and Accountability Act (HIPAA). In general, we cannot use or share your health 
information for research without your permission. If you want, we can give you more 
information about the Privacy Rule. Also, if you have any questions about the Privacy Rule 
and your rights, you can speak to Yale Privacy Officer at 203-432-5919. 
 




















• Research study records 
• Medical and laboratory records of only those services provided in connection with 
this Study.   
• The entire research record and any medical records held by Yale New Haven 
Hospital created from: 12/01/2019 to: 12/01/2021 
• Records about phone calls made as part of this research 
• Records about your study visits 
• Information obtained during this research regarding 
▪ HIV / AIDS test results 
▪ Hepatitis infection 
▪ Sexually transmitted diseases 
▪ Other reportable infectious diseases 
▪ Physical exams 
▪ Laboratory, x-ray, biopsy and other test results 
▪ Diaries and questionnaires 
▪ The diagnosis and treatment of a mental health condition 
▪ Use of illegal drugs or the study of illegal behavior 
▪ Records about any study drug you received 
 
 
How will you use and share my information? 
We will use your information to conduct the study described in this consent form.  
We may share your information with: 
• The U.S. Department of Health and Human Services (DHHS) agencies 
• Representatives from Yale University, the Yale Human Research Protection 
Program and the Institutional Review Board (the committee that reviews, approves, 
and monitors research on human participants), who are responsible for ensuring 
research compliance.  These individuals are required to keep all information 
confidential.  
• The U.S. Food and Drug Administration (FDA) This is done so that the FDA can 
review information about [the new drug product or device] involved in this research.  
The information may also be used to meet the reporting requirements of drug 
regulatory agencies.   
• The study sponsor or manufacturer of study drug/device 
• Drug regulatory agencies in other countries 
• Governmental agencies to whom certain diseases (reportable diseases) must be 
reported 
• Health care providers who provide services to you in connection with this study. 
• Laboratories and other individuals and organizations that analyze your health 
information in connection with this study, according to the study plan. 
• Co-Investigators and other investigators  
• Study Coordinator and Members of the Research Team  
• Data and Safety Monitoring Boards and others authorized to monitor the conduct of 
the Study  
 
We will do our best to make sure your information stays private. But, if we share 
information with people who do not have to follow the Privacy Rule, your information will 





However, to better protect your health information, agreements are in place with these 
individuals and/or companies that require that they keep your information confidential. 
 
Why must I sign this document? 
By signing this form, you will allow researchers to use and disclose your information 
described above for this research study. This is to ensure that the information related to 
this research is available to all parties who may need it for research purposes. You always 
have the right to review and copy your health information in your medical record.  
 
What if I change my mind? 
The authorization to use and disclose your health information collected during your 
participation in this study will never expire.  However, you may withdraw or take away your 
permission at any time. You may withdraw your permission by telling the study staff or by 
writing to Dr. Michael Hurwitz, 20 York Street, New Haven, CT, 06510 at the Yale 
University, New Haven, CT 06520. 
If you withdraw your permission, you will not be able to stay in this study but the care you 
get from your doctor outside this study will not change.  No new health information 
identifying you will be gathered after the date you withdraw. Information that has already 
been collected may still be used and given to others until the end of the research study to 
insure the integrity of the study and/or study oversight.   
 
Who will pay for treatment if I am injured or become ill due to participation in the 
study?  
If you are hurt or injured during this research, you will be given the medical care you may 
need, but you or your insurance company will be billed for the cost of this treatment. No 
financial compensation is available for injury or lost wages. You do not give up any of 
your legal rights by signing this consent form. 
 
What if I want to refuse or end participation before the study is over?  
Taking part in this study is your choice. You can choose to take part, or you can choose 
not to take part in this study.  You also can change your mind at any time.  Whatever 
choice you make, you will not lose access to your medical care or give up any legal 
rights or benefits.  
We would still treat you with standard therapy or, at your request, refer you to a clinic or 
doctor who can offer this treatment. Not participating or withdrawing later will not harm 
your relationship with your own doctors or with this institution.   
To withdraw from the study, you can call a member of the research team at any time and 
tell them that you no longer want to take part.   
 
The researchers may withdraw you from participating in the research if necessary, e.g. 
because of development of serious side effects. 
 
What will happen with my data if I stop participating? 
When you withdraw your permission, no new health information identifying you will be 
gathered after that date. Information that has already been gathered may still be used 
and given to others until the end of the research study, as necessary to insure the 






Who should I contact if I have questions?  
Please feel free to ask about anything you don't understand.  
If you have questions later or if you have a research-related problem, you can call the 
Principal Investigator Dr.Michael Hurwitz at (203) 400-4822.  
If you have questions about your rights as a research participant, or you have complaints 
about this research, you call the Yale Institutional Review Boards at (203) 785-4688 or 
email hrpp@yale.edu. 
 
A description of this clinical trial will be available on http://www.ClinicalTrials.gov, as 
required by U.S. Law. This Web site will not include information that can identify you. At 
most, the Web site will include a summary of the results. You can search this Web site at 
any time. 
Authorization and Permission 
 
Your signature below indicates that you have read this consent document and that you 
agree to be in this study.   
 
We will give you a copy of this form. 
 
 
Participant Printed Name  Participant Signature  Date 
Person Obtaining Consent Printed 
Name 





Complete if the participant is not fluent in English and an interpreter was used to obtain 
consent.  Participants who do not read or understand English must not sign this full consent 
form, but instead sign the short form translated into their native language.  This form should 
be signed by the investigator and interpreter only.  If the interpreter is affiliated with the 






Print name of interpreter: ______________________________________ 
 
Signature of interpreter: ___________________________________    Date: _________ 
 
An oral translation of this document was administered to the participant in 
_____________ (state language) by an individual proficient in English and 
____________ (state language).  
Print name of impartial witness: __________________________________ 
 
Signature of impartial witness: ________________________________Date: _________ 
 
See the attached short form for documentation. 




APPENDIX H IPILIMUMAB AND NIVOLUMAB DOSE CALCULATIONS 
 
A. Ipilimumab 1ml/kg dose, supplied as 5mg/ml (40ml or 10ml single use vials) 
 
To calculate the total dose:  
Patient’s weight in kg x 1mg dose = total dose in mg 
 
To calculate the total infusion volume:  
Total dose in mg / 5mg/ml (as supplied) = total infusion volume in ml  
 
To calculate the infusion rate:  
Total infusion volume in ml / 60minutes = rate of infusion in ml/min  
 
B. Nivolumab 3ml/kg dose supplied as 10mg/ml (4ml, 10ml or 24ml single use vials)  
 
To calculate the total dose:  
Patient’s weight in kg x 3mg dose = total dose in mg 
 
To calculate the total infusion volume:  
Total dose in mg / 10mg/ml (as supplied) = total infusion volume in ml  
 
To calculate the infusion rate:  








Yervoy package insert In: Company Bristol-Myers Squibb, ed. 
Opdivo (nivolumab). In: Bristol-Myers Squibb, ed. [package insert]. www.opdivo.com. 
 
 
APPENDIX I PATIENT REGISTRATION FORM 
 
 
Yale Cancer Center 
Smilow Cancer Hospital 
Yale School of Medicine  
Department of Medical Oncology 
Principal Investigator: Michael Hurwitz, MD, PhD.  
 
Patient’s Name: (Last, First, Middle initial) ______________, _________________, ___ 
Patient Registration Number: 
DOB (MM/DD/YYYY):__/__/____ 
Social Security Number: ___-__-____ 
Demographics: 
Sex assigned at birth: ☐Male ☐Female  
Age: ☐18-24 ☐25-34 ☐35-44 ☐45-54 ☐55-64 ☐65-74 ☐75-84 ☐85-94 
Race: ☐White ☐Hispanic or Latino ☐Black or African American ☐Native 
American or American Indian ☐Pacific Islander or Asian ☐Other 
 
Diagnosis of primary tumor: (MM/DD/YYYY)__/__/____ 
Diagnosis of metastasis: (MM/DD/YYYY)__/__/____ 
Sites of metastasis: _______________________________________________________ 
Histologic characterization of tumor: _________________________________________ 
Confirmed MSS or pMMR ☐  Histochemistry  or ☐  PCR or ☐  MSIsensor   
Date performed (MM/DD/YYYY) __/__/____ 
 
History of Lynch syndrome:  ☐ Yes ☐ No  
Immunoscore:  ☐ 1 ☐ 2 ☐ 3 ☐ 4 
Treatment dates: _________________ Treatment regimen/dose: ___________________  
Treatment dates: _________________ Treatment regimen/dose: ___________________  
















Name: _________________________ Dose:____________________________________ 
Name: _________________________ Dose:____________________________________ 
Name: _________________________ Dose:____________________________________ 
Name: _________________________ Dose:____________________________________ 
Name: _________________________ Dose:____________________________________ 
Name: _________________________ Dose:____________________________________ 
Name: _________________________ Dose:____________________________________ 
Name: _________________________ Dose:____________________________________ 
Name: _________________________ Dose:____________________________________ 
Name: _________________________ Dose:____________________________________ 
 
Allergies: 
Name: ________________________ Reaction:__________________________________ 
Name: ________________________ Reaction:__________________________________ 
Name: ________________________ Reaction:__________________________________ 
Name: ________________________ Reaction:__________________________________ 
Name: ________________________ Reaction:__________________________________ 
Name: ________________________ Reaction:__________________________________ 
 
ECOG performance status 
☐ 0 Fully active, able to carry on all pre-disease performance without restriction 
☐ 1 Restricted in physically strenuous activity but ambulatory and able to carry out work 
of a light or sedentary nature, e.g., light house work, office work 
 
Smoking history:  




APPENDIX J SAMPLE SIZE CALCULATION 
 
 




Probability of early 
stopping 
Interval for w Comment 
37 20 1 6 0.0373 0.8018 29.0  0.4706  [0.7304,1] Minimax 
38 17 1 6 0.0404 0.8077 26.3  0.5576  [0.6853,0.7303]  
39 15 1 6 0.0427 0.8025 24.1  0.6202  [0.2693,0.6852]  
41 14 1 6 0.0500 0.8105 23.4  0.6527  [0,0.2692] Optimal 
   
n is the total number of subjects 





r1, if r1 or fewer responses are observed during stage 1, the trial is stopped early for 
futility 
r2, if r2 or fewer responses are observed by the end of stage two, then no further 
investigation of the drug is warranted 
EN0 is the expected sample size for the trial when response rate is p0 
Interval for w is the set of values w such that the design minimizes w * n + (1 – w) * EN0 
 
The null hypothesis that the true objective response rate is 8.7%, as observed in the 
CheckMate 142 trial will be tested against two one-sided alternatives. A 15% effect size 
will be tested for clinical significance using a Type I (one sided) error rate of 0.5 and type 
II error of 0.2, yielding an 80% power. p1, which is the response probability of the good 
drug is 23.7%, calculated as p0 + 15% effect size. The 15% is an arbitrarily chosen effect 
size that is widely used in cancer drug trials. The Simon’s two stage design calculator 
uses this statistical input to calculate n which is the total number of subjects, n1, the 
number of subjects accrued during stage 1, r1, the value for which if r1 or fewer responses 
are observed during stage 1, the trial is stopped early for futility, r2, the value for which if 
r2 or fewer responses are observed by the end of stage two, then no further investigation 
of the drug is warranted, EN0 which is the expected sample size for the trial when 
response rate is p0 (response probability of poor drug). 
 
References: 
1. Simon R. Optimal two-stage designs for phase II clinical trials. Controlled 
clinical trials. 1989;10(1):1-10. 
2. Jung SH, Lee TY, Kim KM, George S (2004). Admissible two-stage designs for 
phase II cancer clinical trials, Statistics in Medicine 23: 561-569. 





APPENDIX K RESPONSE EVALUATION CRITERIA IN SOLID TUMORS 
(RECIST) V.1.1 
 
ORR: Investigator-assessed objective response rate calculated as patients with best 
response or complete response (CR) or partial response (PR) divided by the number of 
patients treated.  
OS: Time from the first dose to death.  
PFS: Progression free survival defined as time from first dose to first documented 
progression or death resulting from any cause, whichever occurred first.  
DCR: Patients with CR, PR or stable disease (SD) for ≥ 12 weeks divided by the number 
of patients treated.  








APPENDIX L PATIENT STUDY CHECKLIST 
 
Patient’s Name (Last, First, Middle initial): _____________, ________________, _____ 
DOB (DD/MM/YYYY):__/__/____ 
Registration number:  ____________ 
Proposed treatment start date: __/__/____ 
Actual treatment start date: __/__/____ 
 
☐ Passed Eligibility Checklist 
☐ Signed Consent to Participate in Study 
☐ Completed Patient Registration Form  
☐ Randomized to Treatment Arm A or Treatment Arm B  
 
 
APPENDIX M CRITERIA FOR TREATMENT DELAY AND RESUMPTION 
 
Adopted from Supplemental Tables for: Safety of Nivolumab Plus Low-Dose Ipilimumab 
in Previously Treated Microsatellite Instability-High/Mismatch Repair-Deficient 
Metastatic Colorectal Cancer Michael Morse et al. Table S1. For grading of adverse 
events please see Appendix D (CTCAE) Version 5.0 
 
Treatment Delay Criteria: 
 
•Any grade ≥2 non–skin-specific TRAE, with the following exceptions: 
- Grade 2 treatment-related fatigue or laboratory abnormalities do not require a 
treatment delay 
•Any grade 3 skin TRAE 
•Any grade 3 treatment-related laboratory abnormality, with the following exceptions for 
asymptomatic amylase or lipase, AST, ALT, or total bilirubin:  
- Grade 3 amylase or lipase abnormalities that are not associated with symptoms or 
clinical manifestations of pancreatitis do not require a dose delay (consultation 
recommended for grade 3 amylase or lipase abnormalities) 
- In patients with baseline AST, ALT, or total bilirubin within normal limits, treatment 
would be delayed in case of treatment-related grade ≥2 toxicity  
- In patients with baseline AST, ALT, or total bilirubin within the grade 1 toxicity 
range, treatment would be delayed in case of treatment-related grade ≥3 toxicity 
 
Treatment resumption criteria: 
 
Patients can resume treatment when the TRAE resolved to grade ≤1 or to baseline values, 
with the following exceptions: 





•Patients who have not experienced a grade 3 skin TRAE may resume treatment in the 
presence of grade 2 skin toxicity 
•Patients with baseline grade 1 AST/ALT or total bilirubin who require dose delays for 
reasons other than a 2-grade shift in AST/ALT or total bilirubin may resume treatment in 
the presence of grade 2 AST/ALT or total bilirubin 
•Treatment-related pulmonary toxicity, diarrhea, or colitis must have resolved to baseline 
before treatment is resumed 
•Treatment-related endocrinopathies adequately controlled with only physiologic 
hormone replacement may resume treatment 
 
Abbreviations: TRAE – treatment-related adverse events, ALT- alanine aminotransferase, 
AST- aspartate aminotransferase 
 
Reference: 
 Morse MA, Overman MJ, Hartman L, et al. Safety of Nivolumab plus Low-Dose 
Ipilimumab in Previously Treated Microsatellite Instability-High/Mismatch Repair-
Deficient Metastatic Colorectal Cancer. The oncologist. 2019. 
 
APPENDIX N DEFINITIONS OF ADVERSE EVENTS WITH IMMUNE 
CHECKPOINT INHIBITOR THERAPY 
 
Treatment Related Adverse Events (TRAEs) are defined as adverse events (AEs) 
of special clinical interest meeting defined criteria that were grouped by specific 
categories such as endocrine, GI, hepatic, pulmonary, renal and skin events and had a 
potential immunologic etiology.  
Immune mediated adverse events (IMAEs) are defined as specific events that 
includes diarrhea and colitis, hepatitis, pneumonitis, nephritis and renal dysfunction, rash, 
and endocrine events such as adrenal insufficiency, hypophysitis, 
hypothyroidism/thyroiditis, hyperthyroidism and diabetes mellitus.  
 
Reference: 
 Morse MA, Overman MJ, Hartman L, et al. Safety of Nivolumab plus Low-Dose 
Ipilimumab in Previously Treated Microsatellite Instability-High/Mismatch Repair-
Deficient Metastatic Colorectal Cancer. The oncologist. 2019. 
 
APPENDIX O ADEQUATE ORGAN FUNCTION LABORATORY VALUES 
 
Hematological 
Absolute leukocyte count ≥2500 /mcL 
Absolute lymphocyte count 
(ALC) 
≥500 /mcL 
Absolute neutrophil count 
(ANC) 
≥1500 /mcL 






≥9 g/dL or ≥ 5.6 mmol/L without transfusion or EPO 
dependency (within 7 days of assessment) 
Hepatic 
Serum total bilirubin ≤ 1.5 X ULN 
or or 
Direct bilirubin 
≤ ULN for subjects with total bilirubin levels > 1.5 
ULN 
AST and ALT  
≤ 2.5 X ULN OR 
≤ 5 X ULN for subjects with liver metastases 
Albumin > 2.5 mg/dL 
Coagulation 
International Normalized Ratio 
(INR) or Prothrombin Time 
(PT) 
≤1.5 X ULN unless subject is receiving anticoagulant 
therapy as long as PT or PTT is within therapeutic range 
of intended use of anticoagulants 
Activated Partial 
Thromboplastin Time (aPTT) 
≤1.5 X ULN unless subject is receiving anticoagulant 
therapy as long as PT or PTT is within therapeutic range 
of intended use of anticoagulants 
Renal 
Serum creatinine ≤1.5 X upper limit of normal (ULN) 
or or 
Measured or calculated 
creatinine clearance 
(GFR can also be used in place 
of creatinine or CrCl) 




Eisenhauer EA, Twelves C, Buyse M, Phase I Cancer Trials, a Practical Guide, Oxford 
















APPENDIX P SUMMARY OF CURRENT PHASE I/II TRIALS 





and COX2-inhibition in 
Early Stage Colon 
Cancer: an Unbiased 












60 Early stage (stage 
1-3) CRC (both 
MSS and MSI-H)  
 
Neoadjuvant 
Control arm: single dose 
of ipilimumab 1mg/kg 
on day 1 and two cycles 
of nivolumab 3mg/kg 
on day 1 and 15, 
respectively. 
Experimental group: 
single dose of 
ipilimumab 1mg/kg on 
day 1, two cycles of 
nivolumab 3mg/kg one 
day 1 and 15 and 200mg 
celecoxib daily until the 








Per CTCAE v 4.0 
1. Immune activating 
capacity of short-term pre-
operative immunotherapy 
[Time Frame: within 2 years 
after study completion] 
identify underlying potential 
escape mechanisms by 
comparing pre-treatment 
and post-treatment biopsies 
2. Relapse free survival 
[Time Frame: 3-5 years after 
last patient inclusion] 
RACIN, A Phase I 




























200mg/m2 (IV) Q2W 
from cycle C0 to C4. 
Nivolumab: 240 mg IV 
Q2W from cycle C1 to 
C4.  
Ipilimumab: 1mg/kg 
will be administered as 
IV every 6 weeks 
(Q6W) from cycle C1 to 
C4 Aspirin: 300mg 
orally daily from cycle 
C1 to C4. Dose 
escalation of radiation: 
0.5Gy, 1Gy, 2Gy, 3Gy 







[Time Frame: 3.5 
years] Phase Ia 






1. Objective response rate 
(ORR)[Time Frame: 3.5 
years] Per (RECIST) v.1.1. 
2. Disease Control Rate 
(DCR) [Time Frame: 6,12 
and 24 months] Per RECIST 
v.1.1 
3. Progression free survival 
(PFS) rate 
[Time Frame: 6,12 and 24 
months] Per RECIST v.1.1. 
4. Time to Progression 
(TTP): [Time Frame: 3.5 





[Time Frame: 3.5 
years] 
5. Overall survival (OS) 
[Time Frame: 12 and 24 
months] 
PD-1 Antibody 
Combined With COX 
Inhibitor in MSI-






open label  




PD-1 antibody + cox 
inhibitor BAT1306 + 
aspirin  
BAT1306 100mg on 
day 1 + aspirin 200mg 
oral (celebrex 400mg 
oral when there is 
contraindication to 
aspirin) on day 1-21 
every three weeks  
CR (complete 
response) + PR 
(partial response) 




1. Progression free survival 
[Time Frame: 2 years]  
2. Overall survival time 
[Time Frame: 5 years] 
3. Disease control rate 
[Time Frame: 6 months] 
Per RECIST version 1.1  
4. Toxicity assessed using 
the NCI common toxicity 
criteria, version 4.0. 
[Time Frame: 2 years] 
5. Duration of response 
[Time Frame: 2 years] 
 
An Open Label Phase II 
Study Combining 
Nivolumab and 
Celecoxib in Patients 













68 Cancer types with 





expression of tumor 
cells) and non T-
cell infiltrated 
tumors (<1% T 
cells infiltrating the 
tumor bed) 
Celecoxib 400 mg/d 
nivolumab 240 mg 
every two weeks 
ORR Objective 
response rate 
[Time Frame: at 





related adverse events as 
assessed by CTCAE v4.0 
[Time Frame: from first 
dose to day 28 post last 
dose] 
2. Efficacy - Duration of 
response (DOR) 
[Time Frame: From date of 
randomization until the date 
of first documented 
progression or date of death 
from any cause, whichever 
came first, assessed up to 60 
months] 
per RECIST v1.1 
3. Efficacy - Time to 
response (TTR) 





treatment to response of 
cancer through study 
completion, an average of 
12 months is expected] Per 
RECIST v1.1. 
4. Disease control rate 
(DCR) [Time Frame: at 
week 12 from onset of 
treatment] 
Per RECIST v1.1. 
5. Progression-free survival 
(PFS) [Time Frame: From 
date of randomization until 
the date of first documented 
progression or date of death, 
whichever comes first, 
assessed up to 60 months ] 
Per RECIST v1.1), or death 
due to any cause, if 
occurring sooner than 
progression. 
6. Overall survival (OS) 
[Time Frame: From date of 
randomization until the date 
of death, assessed up to 60 
months] 
PRIMMO: a phase II 
study combining PD-1 
blockade, radiation and 
immunomodulation to 







cohort study with 







q3w IV, Radiation 3 
fractions of 8Gy 48 
hours apart, Vitamin D 
2000IU daily, 
Lansoprazole 180mg 
uneven weeks, 30mg 
even weeks, aspirin 
325mg daily, cyclo-
phosphamide 50mg 
daily, curcumin 2g daily 
Objective 
response rate 




Safety per (CTCAE4.0), the 
ORR at week 26 per 
RECIST criteria, the best 
overall response (BOR), 
progression-free survival 
(PFS), overall survival (OS) 






APPENDIX Q DEFINITION OF ADVERSE EVENTS AND SERIOUS ADVERSE 
EVENTS 
 
Adverse events (AE) are defined as any untoward or unfavorable occurrence in a 
human research subject (physical or psychological harm) temporally associated with the 
individual’s participation in the research (whether or not considered related to 
participation in the research). 
 
Serious adverse events (SAE)  are defined as any adverse event that results in any 
of the following outcomes: death, a life-threatening experience, inpatient hospitalization 
or prolongation of existing hospitalization, a persistent or significant 
disability/incapacity, a congenital anomaly/birth defect, or any other adverse event that, 
based upon appropriate medical judgment, may jeopardize the subject’s health and may 




Administration OoR. IRB Policy 710  Reporting Unanticipated Problems Involving Risks 
to Subjects or Others, including Adverse Events. In: University Y, edApril 15 
2014  
 
APPENDIX R BRIEF OUTLINE OF AMERICAN SOCIETY OF CLINICAL 
ONCOLOGY (ASCO) GUIDELINES BY CTCAE GRADE 
 
There will be a high level of suspicion that any new adverse symptom might be 
immunotherapy related. In general, Grade 1 toxicities will be closely followed without 
treatment interruption. Exceptions are some neurologic, cardiac and hematologic 
toxicities. Treatment will be held for most Grade 2 toxicities and will be resumed when 
symptoms and/or laboratory abnormalities revert to Grade 1 or less. A 0.5-1.0mg/kg/day 
prednisone equivalent corticosteroid dose may be administered.  
Treatment will be held for Grade 3 toxicities and high dose corticosteroids will be 
initiated (prednisone equivalent of 1-2mg/kg/day, (alternatively methylprednisolone IV 
1-2mg/kg/day). Infliximab may be given if symptoms and/or laboratory values don’t 
improve within 48-72 hours with high dose corticosteroids.  In case of liver toxicity, we 
will use non-TNF-α agents instead to avoid the hepatotoxic properties of Infliximab. 
Treatment might be reinitiated when symptoms and/or laboratory values return to Grade 
1 or less. There will be no dose adjustments made. Treatment will be permanently 
discontinued in case of Grade 4 toxicity, except for endocrinopathies that can be 
generally managed by hormone replacement.  
 
Reference: 
Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of Immune-Related Adverse 
Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American 
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